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Integration of the reverse transcribed viral cDNA into the host cellular genome is an 
essential event during the replication cycle of HIV-1. This step is catalyzed by the 
viral integrase (IN) protein, which has been identified as a substrate for acetylation 
by the cellular histone acetyltransferase (HAT) p300 (Cereseto et al., 2005; Topper 
et al., 2007). The modified residues have been mapped to the IN C-terminal 
domain (CTD), corresponding to lysines 264, 266 and 273 (Cereseto et al., 2005; 
Topper et al., 2007). While IN acetylation by p300 was shown to increase both IN 
binding affinity to DNA and its strand transfer activity in vitro (Cereseto et al., 
2005), conflicting results were obtained regarding the relevance of this post-
translational modification (PTM) of IN during HIV-1 replication, with one study 
reporting a severe replication impairment for a mutant viral clone in which lysine-to-
arginine substitutions were introduced at the IN sites targeted by p300-mediated 
acetylation (Cereseto et al., 2005), and a subsequent report claiming that the virus 
expressing the acetylation-defective mutant IN was able to replicate with kinetics 
similar to the wild type virus (Topper et al., 2007). 
Based on these premises, the aim of the present thesis was that of investigating 
the role of IN acetylation by cellular HATs during HIV-1 integration and how this 
PTM influences the viral replication cycle. Since proteins modified by acetylation 
are often substrates for multiple HATs, we set out to explore whether IN might be 
acetylated by enzymes other than p300 and indeed found the existence of a 
physical and functional interaction between IN and the member of the GNAT family 
of HATs GCN5, resulting in the acetylation of four lysines in the IN CTD, at 
positions 258, 264, 266 and 273. Given that IN lysines 264, 266 and 273 proved to 
be common substrates of GCN5 and p300, we decided to perform a comparative 
analysis of the roles played by these enzymes during HIV-1 integration and 
replication. With the present study we obtained results supporting the notion that 
HIV-1 integration is modulated by an acetylation balance that controls the activity 
of the IN enzyme and involves at least two different cellular HATs, GCN5 and 
p300. Finally, the identification of a novel pathway of IN regulation unveils a new 

















HIV-1 and AIDS 
The Human Immunodeficiency Virus (HIV) is a member of the genus Lentivirus in 
the Retroviridae family. Retroviruses are so called because, upon entry into the 
host cell, their RNA genome is reverse transcribed into a DNA copy that is stably 
inserted into the cellular chromosomal DNA. The integrated form of the viral DNA, 
the provirus, then serves as template for the formation of viral RNAs and proteins 
that constitute the progeny virions. The reverse flow of genetic information from 
RNA to DNA and the establishment of the viral DNA in an integrated form in the 
host cell genome are the defining hallmarks of retroviruses. 
Since its initial description in 1983, HIV type 1 (HIV-1) was identified as the 
etiological agent of the acquired immunodeficiency syndrome (AIDS) (Barre-
Sinoussi et al., 1983; Broder and Gallo, 1984; Gallo et al., 1984), a clinical 
condition characterized by profound immunosuppression with associated 
opportunistic infections and malignant tumors, wasting, and central nervous system 
(CNS) degeneration. 
Even if the AIDS epidemic was first identified only in the 1980s, the degree of 
morbidity and mortality caused by HIV and the global impact of HIV infection on 
health care resources and economics are already enormous. Although HIV 
incidence has been steadily declining since the late 1990s, levels of new infections 
are still high, and, with significant reductions in mortality due to the scale up of 
antiretroviral therapy over the past few years, the number of people living with HIV 
worldwide has increased: UNAIDS estimated that there were about 33 million 
people living with HIV infection and AIDS worldwide at the end of 2009 (UNAIDS, 
2010). 
The structure of HIV-1 
The morphologic structure of the viral particle 
HIV-1 particles are around 120 nm in diameter and roughly spherical. The viral 
genome consists of two copies of a single stranded RNA about 9500 nucleotides 
(nt) long and is tightly associated with the nucleocapsid protein p7. This 
ribonucleoprotein complex is enclosed by a conical capsid made up of the viral 
protein p24. The capsid environment also contains other viral proteins, such as 
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reverse transcriptase and integrase. The capsid is surrounded by a layer of matrix 
protein, p17, which is in turn anchored to the inside of the viral lipoprotein 
membrane, the envelope. This is formed when the virus buds from the infected cell, 
taking some of the host plasma membrane with it. The major HIV-1 proteins 
associated with the envelope are gp120 and gp41. The gp41 transmembrane (TM) 
subunit traverses the envelope, while the gp120 surface (SU) subunit is present on 
the outer surface and is non-covalently linked to gp41, thus forming a complex that 
mediates the attachment to target cells. Also enclosed within the virion are the viral 
protease and the accessory proteins Vif, Vpr and Nef. The structure of a HIV-1 
mature virion is schematically represented in Figure 1. 
 
Figure 1. Schematic representation of a mature HIV-1 virion. (Abbas, 2010). 
The organization of the viral genome 
The HIV-1 genome is comprised of nine open reading frames (ORFs). The gag 
(group-specific antigen), pol (polymerase) and env (envelope) ORFs encode the 
classical structural and enzymatic precursor polyproteins, which are subsequently 
cleaved into the individual components common to all retroviruses (Figure 2). The 
four Gag proteins, p17 matrix (MA), p24 capsid (CA), p7 nucleocapsid (NC) and 
p6, together with the two Env proteins, gp120 and gp41, are the structural 
components that make up the core of the virion and the outer membrane envelope. 
The three pol-encoded proteins, protease (PR), reverse transcriptase (RT) and 
integrase (IN), provide essential enzymatic functions and are also included within 
the viral particle. In addition to the products of the gag, pol and env genes, HIV-1 
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genome encodes six additional proteins (Figure 2), often called accessory proteins: 
two expression enhancing factors, Tat (transactivator of transcription) and Rev 
(regulator of expression of the virion), as well as four proteins that modulate cell 
systems and functions for the advantage of the virus, Vif (viral infectivity factor), 
Vpu (viral protein U), Nef (negative factor), and Vpr (viral protein R). 
Long terminal repeats (LTRs) at each end of the viral genome are generated 
during the process of reverse transcription and, therefore, exist only as repeats in 
the viral DNA. In the context of the provirus, the major function of the LTRs 
consists in the regulation of viral RNA synthesis. The 5’ LTR normally acts as the 
HIV-1 transcriptional promoter, whose function is to recruit the RNA polymerase II 
(RNA pol II) holoenzyme to the start site of viral RNA synthesis, while the 3' LTR 
acts in transcription termination and polyadenylation. 
 
Figure 2. Schematic representation of the proteins encoded by HIV-1 proviral DNA. (Freed, 2004). 
The HIV-1 replication cycle: an overview 
The replication cycle of HIV-1 is a complex multistep process that depends on both 
viral and host cell factors (Figure 3) (Fields et al., 2007). The first step in HIV-1 
infection involves the interaction between the virion SU gp120 protein and the 
primary receptor CD4 expressed on T-lymphocytes, T-cell precursors within the 
bone-marrow and thymus, monocytes and macrophages, eosinophils, dendritic 
cells and microglial cells of the CNS (Wyatt and Sodroski, 1998). CD4 binding 
induces conformational changes in gp120, resulting in the exposure of the 
coreceptor-binding determinants (Sullivan et al., 1998). The two major coreceptors 
required for entry of HIV-1 are the chemokine receptor molecules CCR5 and 
CXCR4 (Alkhatib et al., 1996; Choe et al., 1996; Deng et al., 1996; Feng et al., 
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1996), which are used by monocyte/macrophage (M)-tropic strains (R5 isolates) 
and T-cell (T)-tropic viruses (X4 isolates), respectively (Berger et al., 1998). The 
final step for viral entry requires the gp41-mediated fusion of the viral envelope 
components with the host cell membrane. The current model to explain membrane 
fusion assumes that, after the formation of a ternary gp120-CD4-coreceptor 
complex, conformational changes occurr in gp41 that lead to the exposure of its N-
terminal part. This part, also known as the fusion-peptide, is then inserted into the 
target lipid bilayer (Eckert and Kim, 2001), triggering the fusion of the HIV-1 
envelope with the host cell membrane and virus internalization. 
Following entry of the HIV-1 core into the cytoplasm of the target cell, reverse 
transcription of the viral genomic RNA into a linear double-stranded cDNA copy 
takes place within a large macromolecular complex, known as the reverse 
transcription complex (RTC), which comprises proteins of both cellular and viral 
origin (Fassati and Goff, 2001; Karageorgos et al., 1993). The enzyme that 
catalyzes the reaction is RT. RT possesses three catalytic activities essential for 
replication of the virus: RNA-dependent DNA polymerase (i.e. reverse 
transcriptase), RNase H (i.e. for degradation of the genomic RNA in RNA/DNA 
hybrids during DNA synthesis) and DNA-dependent DNA polymerase activity (i.e. 
for synthesis of the second strand of the viral cDNA) (Fields et al., 2007). 
The next step in the replication cycle is the translocation of the viral double-
stranded cDNA into the nucleus as a component of a large nucleoprotein complex 
called the pre-integration complex (PIC), which is composed of both viral and 
cellular proteins (Bukrinsky et al., 1993b; Farnet and Haseltine, 1991; Miller et al., 
1997). To cross the intact nuclear envelope and enter the nucleus, the PIC must be 
actively transported through the nuclear pore complex (NPC). Many attempts have 
been made to determine the viral and cellular factors mediating nuclear import of 
the HIV-1 PIC. Various viral karyophilic proteins, such as MA, Vpr and IN have 
been suggested to actively translocate the PIC into the host cell nucleus (Bukrinsky 
et al., 1993b; Depienne et al., 2000; Farnet and Haseltine, 1991; Haffar et al., 
2000; Jenkins et al., 1998; Miller et al., 1997; Sherman and Greene, 2002; Zennou 
et al., 2000). The cellular protein lens epithelium-derived growth factor p75 
(LEDGF/p75), along with a short section of triple-stranded DNA present within the 
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viral cDNA and known as the DNA flap, have also been implicated in promoting 
translocation of the PIC into the nuclei of infected cells (Cherepanov et al., 2003; 
Llano et al., 2004b; Zennou et al., 2000). In addition, CA recently emerged to play 
a key role in mediating HIV-1 nuclear import (Yamashita and Emerman, 2004) 
(Yamashita et al., 2007). With regard to cellular cofactors, several nuclear-import 
receptors, such as the importin α/β heterodimer (Ao et al., 2005; Armon-Omer et 
al., 2004; Gallay et al., 1997; Hearps and Jans, 2006; Levin et al., 2009), importin 7 
(Ao et al., 2007; Zaitseva et al., 2009) and transportin-SR2 (TRN-SR2, TNPO3, 
transportin 3) (Brass et al., 2008; Christ et al., 2008; Konig et al., 2008), as well as 
several components of the nuclear pore complex, among which Nup 98, Nup153 
and RanBP2 (Nup358) (Brass et al., 2008; Ebina et al., 2004; Konig et al., 2008; 
Woodward et al., 2009; Zhang et al.), were all proposed to be required for efficient 
translocation of the HIV-1 PIC into the host cell nucleus. However, at present, the 
exact mechanism governing nuclear import of the HIV-1 PIC still awaits further 
clarification. 
Following the PIC arrival in the nucleus, the viral IN protein catalyzes the 
integration of HIV-1 cDNA into the host cellular genome. The integration reaction 
and the host factors participating in the process will be discussed in full detail in the 
next section. 
The integrated viral DNA is then transcribed, thus generating full-length progeny 
viral RNA and a number of spliced mRNA transcripts to be translated in the 
cytoplasm (Coffin et al., 1997). Transcription of HIV-1 proviral DNA is broadly 
similar to host gene transcription and involves a large array of cellular 
transcriptional activator and repressor proteins, as well as the entire RNA Pol II 
machinery. An exception is represented by the enhancement of expression from 
the HIV-1 LTR promoter, which is mediated by the viral regulatory protein Tat. Tat 
is an atypical transcriptional activator, since it does not bind to DNA, but to a RNA 
stem-loop structure, the transactivation response region (TAR), which forms at the 
5′-end of nascent HIV-1 transcripts (Berkhout et al., 1989; Dingwall et al., 1989). 
Through its interaction with TAR, Tat activates transcription from the HIV-1 LTR by 
at least two different molecular mechanisms. The first mechanism consists in the 
recruitment of the cellular cofactor P-TEFb (positive transcription elongation factor 
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b), composed of the subunits cyclin T1 and CDK9 kinase. Tat interaction with cyclin 
T1 (Wei et al., 1998) increases its binding affinity to the TAR element, thus 
resulting in the formation of a ternary Tat/P-TEFb/TAR complex, which brings the 
kinase activity of P-TEFb in the proximity of the HIV-1 promoter. The Cdk9 subunit 
of P-TEFb then phosphorylates the carboxyl-terminal domain (CTD) of the host cell 
RNA pol II, which stimulates the elongation process and thereby the overall 
transcriptional efficiency (Bieniasz et al., 1999; Chen et al., 1999; Fujinaga et al., 
1998; Garber et al., 1998; Ivanov et al., 1999). The second mechanism of Tat-
induced transcriptional activation involves the recruitment of chromatin-modifying 
complexes to the HIV-1 promoter (Benkirane et al., 1998; Col et al., 2001; Hottiger 
and Nabel, 1998; Marzio et al., 1998)((Agbottah et al., 2006; Mahmoudi et al., 
2006), which results in an increased DNA accessibilty to transcription factors and 
activators, thus promoting transcription initiation and efficient elongation. 
The nuclear export of unspliced or partially spliced HIV-1 messages to the 
cytoplasm requires the action of the viral regulatory protein Rev. In the absence of 
Rev function, incompletely spliced HIV-1 mRNAs, primarily encoding viral structural 
proteins, are retained in the nucleus by cellular mRNA-processing factors, known 
as splicing commitment factors (Chang and Sharp, 1989; Emerman et al., 1989; 
Malim et al., 1989). Although these commitment factors can prevent incompletely 
spliced mRNAs from accessing the canonical cellular mRNA-export pathway, they 
cannot prevent the nuclear export of HIV-1 mRNAs bound by Rev. Rev contains an 
RNA binding motif that directly interacts with a stem-loop secondary structure, 
termed the Rev responsive element (RRE), which is present in all incompletely 
spliced viral mRNAs. The RRE can accommodate the binding of at least 8 Rev 
molecules and, at a certain threshold concentration of Rev protein in the nucleus, 
functional Rev/RRE complexes are formed, which greatly stimulate the export of 
unspliced and singly spliced mRNAs to the cytoplasm. The nuclear export of Rev 
with its RNA cargo is mediated by the cellular nucleocytoplasmic transport factor 
Crm1 (chromosome region maintenance 1), which interacts with the Rev nuclear 
export signal (NES) sequence (Fornerod et al., 1997; Fukuda et al., 1997; Stade et 
al., 1997). Once in the cytoplasm, the complex disassembles (Gorlich and Mattaj, 
1996; Nigg, 1997) and Rev is released along with its unspliced or partially spliced 
Introduction 
 21 
HIV-1 RNA cargo, allowing the latter to be incorporated into progeny virions or 
translated into viral proteins. The nuclear import of Rev is then achieved through 
the direct interaction of its nuclear localization signal (NLS) motif with the cellular 
cofactor importin β (Henderson and Percipalle, 1997; Szebeni et al., 1997), which 
results in the translocation of the complex through the nuclear pore. 
HIV-1 assembly takes place in lipid rafts, plasma membrane microdomains 
enriched in cholesterol and glycosphingolipid (Ono and Freed, 2005), and is 
directed by Gag. The MA domain of Gag appears to be responsible for both 
directing the association of the polyprotein with the lipid bilayer and determining the 
specificity of membrane targeting (Facke et al., 1993) (Freed et al., 1994; Ono et 
al., 2000), while the CA domain seems to play a key role in driving the viral particle 
assembly (Ehrlich et al., 1992; Gross et al., 1997; von Schwedler et al., 1998). The 
third major domain synthesized as part of the Gag precursor is NC, whose main 
function in assembly involves the encapsidation of full-length, unspliced HIV-1 
genomic RNA into virions through specific interaction with a cis-acting target known 
as packaging signal or ψ-site (Berkowitz et al., 1996). 
Virus particle production is completed upon budding of the nascent virion from the 
plasma membrane (Adamson and Freed, 2007). To allow virus release from the 
infected cell, the p6 domain of Gag uses its highly conserved Pro-Thr-Ala-Pro 
(PTAP) motif (Huang et al., 1995), also known as “late domain” (since point 
mutations in this motif block the virus release at a late stage), to recruit 
components of the cellular endosomal sorting machinery, which normally function 
to promote the budding of vesicles into late endosome to form multivesicular 
bodies (MVBs) (Bieniasz, 2009; Demirov and Freed, 2004; Fujii et al., 2007; Morita 
and Sundquist, 2004). Concomitant with virus release, PR cleaves the Gag and 
Gag-Pol precursors into their respective protein domains (Coffin et al., 1997), 
leading to virion maturation, a reassembly event that results in the formation of the 
characteristic cone-shaped core and is essential for the acquisition of infectivity 
(Adamson and Freed, 2007; Ganser-Pornillos et al., 2008). Only after maturation is 




Figure 3. Schematic representation of the HIV-1 replication cycle. (Peterlin and Trono, 2003). 
HIV-1 integration 
A distinguishing feature of retroviral replication is the insertion of a DNA copy of the 
genomic RNA into a chromosome of the host cell following reverse transcription. 
The provirus then serves as the template for the synthesis of viral RNAs and is 
maintained as part of the host cell genome for the lifetime of the infected cell. 
Retroviral mutants deficient in the ability to integrate generally fail to establish a 
productive infection. 
The integration reaction is catalyzed by the viral IN enzyme, a 32 kDa protein of 
288 aminoacids generated by PR-mediated cleavage of the C-terminal portion of 
the HIV-1 Gag-Pol polyprotein. 
IN structural overview 
HIV-1 IN is made up of three structurally and functionally distinct domains: the N-
terminal domain (NTD) spanning residues 1 to 50, the protease-resistant central 
catalytic core domain (CCD) from amino acids 50 to 212, and the C-terminal 
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domain (CTD) from residues 212 to 288 (Chiu and Davies, 2004; Jaskolski et al., 
2009) (Figure 4). Among retroviral INs, the NTD and CCD share regions with a 
high degree of sequence similarity, while the CTD is much less conserved. 
 
Figure 4. HIV-1 IN domain organization. Adapted from (Pommier et al., 2005). 
It is not yet possible to crystallize the entire 288-aminoacid HIV-1 IN protein 
because of its low solubility and propensity to aggregate. The structure of all three 
domains, however, has been solved independently by x-ray crystallography or 
nuclear magnetic resonance (NMR) methods. In addition, structures are available 
for HIV- 1 IN fragments containing the NTD plus CCD (Wang et al., 2001), or the 
CCD plus CTD (Chen et al., 2000). 
The NTD contains a conserved zinc-binding motif HHCC (His-12, His-16, Cys-40 
and Cys-43) that coordinates one zinc atom (Zheng et al., 1996), though the 
structure of this region does not resemble that of zinc finger domains involved in 
DNA-binding (Lodi et al., 1995). Consistently, one known function of the HIV-1 IN 
NTD is to contribute to protein multimerization. 
The CCD contains the catalytic DDE motif, which is conserved among all retroviral 
INs and consists of the active site residues Asp-64, Asp-116 and Glu-152 
(Engelman and Craigie, 1992; Kulkosky et al., 1992; Rowland and Dyke, 1990). 
Mutation of any one of these three residues is sufficient to inactivate IN (Engelman 
and Craigie, 1992; Leavitt et al., 1993; van Gent et al., 1992). Crystal structures of 
the HIV-1 IN CCD were only obtained after extensive mutagenesis studies, which 
identified mutants with enhanced solubility (Bujacz et al., 1996; Dyda et al., 1994; 
Goldgur et al., 1999; Jenkins et al., 1995). These structures show that the HIV-1 IN 
CCD binds one Mg2+ ion between Asp-64 and Asp-116. Since Avian Sarcoma 
Virus (ASV) IN binds an additional Zn2+ or Cd2+ ion between Asp-64 and Glu-157 
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(the ortholog of Glu-152) (Bujacz et al., 1997), it is likely that the HIV-1 IN active 
site also binds two metal ions (Mg2+ or Mn2+) when complexed with the ends of the 
viral DNA during the cleavage and joining reactions. Another structural feature of 
the CCD is the 10-aminoacid flexible loop encompassed between residues Gly-140 
and Gly-149. These two residues potentially act as hinges for the overall 
movement of the loop that may serve as a clamp for the binding of the viral DNA 
ends to the catalytic site of IN. Consistent with this possibility, Gln-148, one of the 
flexible loop residues, has been shown to selectively bind to the penultimate 
cytosine at the 5’-end of the viral DNA (Johnson et al., 2006). Gln-148 is also a key 
residue for IN catalytic activity and resistance to IN inhibitors raltegravir and 
elvitegravir (Marinello et al., 2008). 
The CTD is considerably less conserved among retroviral INs than are the other 
domains of the protein. The structure of the isolated CTD of HIV-1 IN was solved 
using NMR (Eijkelenboom et al., 1995; Lodi et al., 1995) and showed a folding 
topology that is reminiscent of Src homology 3 (SH3) domains found in many 
proteins that interact either with other proteins or with nucleic acids (Musacchio et 
al., 1992; Yu et al., 1992), although no sequence similarity to SH3 proteins could 
be detected. The HIV-1 IN CTD possesses non-specific DNA binding activity and 
seems to be important for the binding of the viral DNA ends, thus conferring to IN 
the ability to remain associated with the viral genome during reverse trancription 
(Esposito and Craigie, 1998; Heuer and Brown, 1997; Heuer and Brown, 1998; 
Jenkins et al., 1997). 
Direct physical measurements of purified IN, as well as cross-linking experiments 
and in vitro complementation between defective variants of IN, provided compelling 
evidence that retroviral IN is a multimeric enzyme (Ellison et al., 1995; Engelman et 
al., 1993; Grandgenett et al., 1978; Jones et al., 1992; van Gent et al., 1993). 
While each of the HIV-1 IN domains forms dimers, IN appears to function as a 
tetramer (Cherepanov et al., 2003; Li et al., 2006; Wang et al., 2001). Indeed, a 
tetramer would be the minimal IN multimer to provide a pair of active sites with the 
expected spacing for the concerted integration of two viral DNA ends, and the two-
domain NTD-CCD construct has been shown to crystallize in a tetrameric form, 
best described as a dimer-of-dimers (Hare et al., 2009; Wang et al., 2001). The 
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crystal structure of full-length IN from the prototype foamy virus (PFV) in complex 
with its cognate viral DNA also showed that the organization of the minimal 
functional complex involving viral DNA and IN, the so-called intasome, comprises 
an IN tetramer tightly associated with a pair of viral DNA ends (Hare et al.). 
The mechanism of integration 
The integration reaction biochemically occurs in two steps (Figure 5) following 
reverse transcription and binding of IN to the viral DNA ends in the context of the 
PIC (Vandegraaff and Engelman, 2007). Assembly of the PIC onto the 5’-GCAGT-
3’ sequence of the viral DNA ends forms a complex competent for integration, 
although, in vitro, only IN and DNA are required. The first step, named 3’-end 
processing, is an endonucleolytic cleavage, which results in the removal of two 
nucleotides from the 3’-ends of each viral DNA strand immediately 3’ from the 
conserved CA dinucleotide (5’-GCAGT-3’); a 5’-GT-3’ dinucleotide is generally 
released, resulting in recessed 3’-OH ends at each terminus of the viral DNA. The 
phosphodiester bond in the viral DNA strand is hydrolyzed by water as the 
nucleophile in the presence of Mg2+ (the presumably physiological metal) or Mn2+ 
(Esposito and Craigie, 1998). Following nuclear translocation of the PIC, IN 
catalyzes the second transesterification reaction, known under the name of strand 
transfer, where the recessed 3’-OH ends of the viral DNA act as nucleophiles to 
attack the DNA phosphodiester backbone of a host chromosome. HIV-1 IN 
positions the two viral ends to attack both strands of the host acceptor DNA, with a 
five base pair (bp) gap on each strand. The result is a staggered insertion that is 
subsequently sealed by host DNA repair enzymes. The HIV-1 provirus is flanked 
by a 5 bp direct repeat and terminates with the dinucleotides 5′-TG and CA-3′. The 
direct repeat results from the duplication of the cellular target sequence. 
In addition to the linear, double-stranded viral cDNA that serves as the substrate 
for integration, two types of extrachromosomal viral DNA molecules are observed 
in the nucleus of HIV-1 acutely infected cells. These are circular DNA forms: 1-LTR 
circles, generated through homologous DNA recombination, and 2-LTR circles, 
produced by the nonhomologous end-joining pathway (Brown et al., 1989; 
Bukrinsky et al., 1993a). Although 1-LTR and 2-LTR circles are not substrates for 
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integration, they provide useful markers for nuclear import of the viral DNA, since 
their formation requires the enzymatic machinery present in the nucleus. 
Our understanding of the chemistry of the retroviral integration reaction, as well as 
the screening of HIV-1 IN inhibitors, have been greatly assisted by the 
development of in vitro integration assays, where purified recombinant IN carries 
out 3’-end processing and strand transfer reactions in the presence of short 
synthetic oligonucleotides that mimic the viral DNA ends and a divalent metal ion 
(Mg2+ or Mn2+) (Craigie et al., 1990; Debyser et al., 2001; Katz et al., 1990; 
Marchand et al., 2001). 
 
Figure 5. Outline of the integration reaction. (Van Maele et al., 2006). 
Integration site selection by HIV-1 
To replicate, a retrovirus must integrate a DNA copy of its genomic RNA into a 
chromosome of the host cell. The selection of cellular integration acceptor sites is 
crucial for both the retrovirus and the host (Bushman, 2001; Coffin et al., 1997). For 
the virus, selection of favorable integration target sites is required for efficient viral 
gene expression (Bisgrove et al., 2005; Jordan et al., 2003; Lewinski et al., 2005). 
For the host, integration can cause adverse events such as activation of proto-
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oncogenes or inactivation of required cellular genes. Indeed, insertional activation 
of oncogenes has been observed in a human gene therapy trial, in which 
integration of a therapeutic retroviral vector near the LMO2 proto-oncogene 
contributed to malignant transformation in several patients (Hacein-Bey-Abina et 
al., 2003a; Hacein-Bey-Abina et al., 2003b). These adverse events have focused 
intense interest on the mechanisms mediating retroviral integration site selection. 
The cellular DNA sequences hosting integration events show modest similarity to 
one another, indicating that retroviral DNA integration is not tightly sequence-
specific (Berry et al., 2006; Carteau et al., 1998; Holman and Coffin, 2005; Stevens 
and Griffith, 1996; Wu et al., 2005). 
Studies using in vitro integration assays allowed the identification of factors 
influencing integration site selection in simplified models. DNA binding proteins 
bound to the target DNA block integration by obstructing the access of PICs to the 
target DNA (Bushman, 1994; Pryciak and Varmus, 1992). In contrast, DNA 
bending proteins, such as nucleosomes, actually promote integration (Pruss et al., 
1994a; Pruss et al., 1994b; Pryciak et al., 1992; Pryciak and Varmus, 1992). On 
the nucleosome, the positions of maximal DNA distortion are particularly favored 
for integration (Pruss et al., 1994a; Pruss et al., 1994b), probably because IN 
distorts its DNA substrates during the reaction cycle (Bushman and Craigie, 1992; 
Katz et al., 2001; Katz et al., 1998; Scottoline et al., 1997). Consistent with this 
notion, prior distortion of the integration target DNA promotes the integration 
reaction. Thus, wrapping of DNA around nucleosomes alone does not inhibit 
integration (Bushman and Craigie, 1992; Scottoline et al., 1997). However, it 
should be noted that the nucleosomal templates used in the above-mentioned 
experiments were all presumed to be in the 10 nm “beads on a string” 
conformation. The consequences on integration deriving from the incorporation of 
such structures into the 30 nm chromatin fibers, or the still higher-order structures 
that comprise the chromosomes, are unknown. 
Several groups have investigated HIV-1 integration targeting in vivo by sequencing 
the junctions between viral and human DNA and analysing their positions in the 
human genome. Following large-scale sequence analysis, the position of 
integration sites in the human genome was compared with that of other annotated 
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features. In the first such study, the distribution of HIV-1 integration sites in the 
chromosomes of a human lymphoid cell line, SupT1, was investigated (Schroder et 
al., 2002). This study revealed that genes are favoured targets for HIV-1 
integration, and subsequent experiments performed in other cell types reached the 
same conclusion (Mitchell et al., 2004; Wu et al., 2003). Further studies 
investigated whether any preferences exist in the location of HIV-1 integration sites 
along transcription units (TUs) (Mitchell et al., 2004; Schroder et al., 2002; Wu et 
al., 2003), but no biases have been found. Evidently, the positive influence of TUs 
on HIV-1 integration extends across their entire length. Gene-rich regions in the 
human genome are depleted in certain classes of repeat DNA sequences (such as 
human endogenous retroviruses, HERVs, and long interspersed nuclear elements, 
LINEs) and enriched in others (such as Alu elements). Therefore, a bias in the 
rates of integration in these different classes of DNA repeats was expected. 
Indeed, HIV-1 integration appears to be disfavoured in HERV elements, 
consistently with favoured HIV-1 integration in genes (Schroder et al., 2002). In 
addition, HIV-1 integration is strongly disfavoured in alphoid repeats (which, in 
humans, are composed of α-satellite DNA). This indicates that centromeric 
heterochromatin, the location of most of the 〈-satellite-containing DNA, is an 
unfavourable target for HIV-1 integration (Carteau et al., 1998; Schroder et al., 
2002). Since centromeric heterochromatin is known to be tightly wrapped by 
specific DNA-binding proteins, it appears that the packing of DNA into centromeric 
heterochromatin renders it less accessible, consequently disfavouring integration. 
Transcriptional profiling analysis has been carried out in some of the cell types 
studied as integration targets, allowing the influence of transcriptional activity on 
integration site selection to be assessed. Some of these transcriptional profiling 
studies were carried out on retrovirus-infected cells (Lewinski et al., 2005; Mitchell 
et al., 2004; Schroder et al., 2002), so that the results reflected the influence of 
infection on cellular gene activity (Corbeil et al., 2001; Mitchell et al., 2003; 
Schroder et al., 2002; van 't Wout et al., 2003). Analysis of the microarray data 
revealed that the median expression level of genes hosting HIV-1 integration 
events is consistently higher than that of all the genes assayed on the microarray. 
Transcriptional profiling studies have also been performed for integration of a HIV-
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based vector in SupT1 cells, demonstrating that genes activated upon infection are 
favoured integration targets (Schroder et al., 2002). 
Since gene-rich regions in the human genome correlate with high densities of CpG 
islands, an analysis of HIV-1 integration frequency near CpG islands was 
performed. CpG islands are chromosomal regions particularly enriched in the rare 
CpG dinucleotide, and usually correspond to gene-regulatory elements that contain 
clustered binding sites for transcription factors. The regions surrounding CpG 
islands appear to be disfavoured for integration by HIV-1 (Mitchell et al., 2004). 
Therefore, in the case of HIV-1, gene-dense regions seem to contain interleaved 
clusters of active genes favouring integration and unfavourable regions that include 
CpG islands. The mechanism by which CpG islands obstruct HIV-1 integration is 
unclear: there might be specific proteins bound at these sites that block integration, 
CpG islands might be located in a nuclear compartment resulting unfavourable for 
integration, or some other as-yet-unknown mechanism might be responsible. 
What mechanisms direct retroviral integration target-site selection in the human 
genome? It has been proposed that retroviral integration is favoured in 
decondensed chromatin, which would be more accessible to the integration 
apparatus (Panet and Cedar, 1977). This notion is supported by genome-wide 
studies, as integration in TUs is favoured in all the data sets for retroviruses and 
other integrating elements (Lewinski et al., 2005; Mitchell et al., 2004; Nakai et al., 
2003; Schroder et al., 2002; Yant et al., 2005). By contrast, integration in highly 
condensed centromeric heterochromatin is disfavoured (Carteau et al., 1998; 
Schroder et al., 2002). However, since the integration target preferences of HIV-1, 
MLV and ASV are so different, it seems unlikely that the accessibility of DNA is the 
only mechanism determining target-site selection. 
Studies on the integration site selection by Ty retrotransponsons in yeast (Boeke 
and Devine, 1998; Bushman, 2003; Sandmeyer, 2003; Zhu et al., 2003), showing 
that Ty integration complexes are tethered to their favoured sites in the host 
genome by interactions with specific cellular proteins, led to the hypothesis that 
such a tethering mechanism might also operate for retroviruses (Bushman, 2003). 
Several studies tested in vitro the feasibility of directing integration into specific 
DNA sites by the use of fusion proteins consisting of HIV-1 IN and a sequence-
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specific DNA-binding protein, such as the phage λ repressor (Bushman, 1994), the 
Escherichia coli LexA repressor (Goulaouic and Chow, 1996; Katz et al., 1996), the 
murine transcription factor Zif268 (Bushman and Miller, 1997), or the synthetic zinc 
finger protein E2C (Tan et al., 2004). The resulting chimeras proved able to direct 
integration by recognizing and binding to their cognate target sites on the DNA, 
causing integration to be mediated into the immediately adjacent regions. 
Subsequent work also demonstrated that the IN-E2C fusion protein, packaged in 
trans into virions, was capable of directing integration of retroviral DNA into a 
predetermined chromosomal region in cultured cells (Tan et al., 2006). All these 
results provided proof of principle that tethering of retroviral IN proteins at target 
sites can promote nearby integration. For HIV-1 PICs, any viral or cellular protein 
present in the complex could theoretically act as binding partner in a tethering 
interaction. Indeed, a number of studies performed in the past few years led to the 
notion that the target site preferences of HIV-1 integration are in part due to 
tethering by the host chromatin-binding protein Ledgf/p75, which interacts with HIV-
1 IN (Cherepanov et al., 2003; Emiliani et al., 2005) and mediates its binding to 
chromatin (Llano et al., 2004b; Maertens et al., 2003). In the absence of Ledgf/p75, 
HIV-1 integration is severely compromised and preferential integration in TUs is 
diminished (Ciuffi et al., 2005; Marshall et al., 2007; Shun et al., 2007b). Recently, 
the tethering model for Ledgf/p75 function was strengthened by the finding that 
fusion proteins containing the IN-binding domain of Ledgf/p75 fused to alternative 
chromatin binding domains are able to efficiently retarget integration (Ferris et al., 
2010; Gijsbers et al., 2010; Silvers et al., 2010). The role of LEDGF/p75 in HIV-1 
integration site selection will be furtherly discussed in the following section. 
Notably, the existence of a link between nuclear entry of the HIV-1 PIC and 
integration targeting was recently hypothesized, based on the finding that the 
cellular proteins TRN-SR2 (TNPO3, transportin 3) and RanBP2 (Nup358), which 
are components of the nuclear import machinery and of the nuclear pore, 
respectively, affect the distribution of HIV-1 integration sites in the host 
chromosomes by regulating the nuclear import of the PIC (Ocwieja et al., 2011). 
According to the proposed model, nuclear translocation through the pore would 
first place the PIC in regions of high gene density, and Ledgf/p75 would then tether 
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the PIC for integration to provide the final distribution in active TUs (Ocwieja et al., 
2011). 
HIV-1 integration and the host cell 
Although purified recombinant IN is necessary and sufficient to carry out 3’-end 
processing and strand transfer reactions in vitro, numerous studies have 
demonstrated that the establishment of the integrated provirus in the infected cell 
also involves a variety of host proteins that can play a role during the different 
steps of the integration process, including nuclear import, IN catalysis, integration 
site selection and DNA gap repair. 
Cellular cofactors of HIV-1 integration 
INI1 
Integrase Interactor 1 (INI1) is part of the mammalian SWI/SNF complex, which is 
implicated in ATP-dependent chromatin remodeling during transcriptional activation 
(Wang et al., 1996); it was first discovered as a binding partner for HIV-1 IN using 
the yeast two hybrid system (Kalpana et al., 1994). The interaction between the 
two proteins is HIV-1 specific (Yung et al., 2004), and INI1 was shown to be 
incorporated into virions (Yung et al., 2001) and to be a component of the reverse 
transcription and pre-integration complexes in the early steps of the viral replication 
cycle (Iordanskiy et al., 2006; Turelli et al., 2001). Furthermore, INI1 was found to 
stimulate the DNA strand transfer catalytic activity of IN in vitro (Kalpana et al., 
1994). 
There have been conflicting results regarding the role played by INI1 during HIV-1 
infection and its necessity. One study found no effects on viral integration in cells 
depleted for INI1 (Boese et al., 2004), whereas other reports suggested that INI1 
might participate in an anti-viral cellular response by interfering with the early steps 
of HIV-1 replication (Maroun et al., 2006; Turelli et al., 2001). Contrastingly, 
another work revealed that INI1 indirectly enhances proviral transcription (Ariumi et 
al., 2006), thus providing evidence of an infectivity-promoting effect of the protein. 
An ectopically expressed dominant negative mutant of INI1, termed S6, containing 
the minimal IN-interaction domain (amino acids 183-294), was found to potently 
inhibit HIV-1 assembly and particle production (Yung et al., 2001). S6 also proved 
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to be an efficient protective agent against HIV-1 infection when stably expressed 
before viral challenge. The inhibitory effects of S6 required the interaction with IN in 
the context of the Gag-Pol polyprotein (Yung et al., 2001). INI1 was also shown to 
be essential for the production of infectious HIV-1 virions (Sorin et al., 2006; Yung 
et al., 2001). In fact, viral particles produced in the absence of INI1 exhibited a 
drastic reduction in viral DNA synthesis, suggesting that the protein may be critical 
for the early events in reverse transcription (Sorin et al., 2006). 
In conclusion, at present, INI1 appears to play dual roles in HIV-1 replication in 
that, while INI1 present in the producer cells seems to be required for HIV-1 
replication, INI1 present in the target cells may be inhibitory. One possibility is that 
cellular INI1 may play a different role than the virally incorporated INI1, explaining 
the observed effects on HIV-1 replication. 
BAF, Lap2α and Emerin 
Barrier-to-Autointegration Factor (BAF) is a cellular component of HIV-1 PICs, 
which blocks suicidal autointegration and stimulates intermolecular integration 
activity in vitro (Chen and Engelman, 1998) (Lin and Engelman, 2003) (Lee and 
Craigie, 1998). This 89-aminoacid protein is highly conserved among multicellular 
eukaryotes and interacts with LEM domain proteins (Lin et al., 2000), which are 
components of the nuclear lamina (Foisner, 2001). It has been suggested that BAF 
mediates the association of the LEM proteins Lamina-associated polypeptide 2 α 
(LAP2α) and emerin to HIV-1 PICS, and that these two proteins, in their turn, target 
the PICs to chromatin, thus promoting integration (Jacque and Stevenson, 2006). 
Depletion of emerin from human cells impaired infection by HIV-1 expressing wild-
type Env or the G glycoprotein from vesicular stomatitis virus (VSV-G), whereas 
depletion of LAP2α reduced infection by HIV-1 harboring wild-type Env, but not by 
HIV-1 pseudotyped with VSV-G (Jacque and Stevenson, 2006). Emerin, in 
particular, appeared to be critical for HIV-1 infection of primary macrophages. 
However, the requirement of LAP2α and emerin for HIV-1 replication has been 
questioned. In fact, subsequent reports demonstrated that cells from emerin 
knockout, LAP2α knockout, or emerin and LAP2α double knockout mice supported 
the same level of HIV-1 infectivity as cells from wild-type littermate mice, indicating 
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that these proteins do not function as universally important regulators of the PIC 
trafficking to chromatin for integration (Shun et al., 2007a) (Mulky et al., 2008). 
Thus, the roles played by emerin and LAP2α in HIV-1 pre-integration trafficking 
and integration still await further clarification. 
HMGA1 
High mobility group chromosomal protein A1 (HMGA1), a non-histone DNA binding 
protein that can modulate transcriptional regulation and chromatin structure (Farnet 
and Bushman, 1997), was proposed as a cofactor of HIV-1 integration due to its 
ability to restore the in vitro integration activity of salt-stripped PICs (Farnet and 
Bushman, 1997). Mechanistic studies pointed to a possible role of the DNA binding 
activity of HMGA1 in approximating the two LTR ends of the viral DNA molecule 
and facilitating IN binding by unwinding the LTR termini (Hindmarsh et al., 1999; Li 
et al., 2000). However, in coimmunoprecipitation experiments, no interaction 
between HMGA1 and HIV-1 IN could be detected (Hindmarsh et al., 1999). 
Consistently, chicken cells lacking HMGA1 are not deficient for retroviral 
integration, suggesting that HMGA1 is not absolutely required for integration 
(Beitzel and Bushman, 2003). In contrast, evidence was provided pointing to an 
important role of HMGA1 during transcription (Henderson et al., 2000; Henderson 
et al., 2004) and splice site regulation of HIV-1 (Tsuruno et al., 2011). 
LEDGF/p75 
Lens epithelium-derived growth factor (LEDGF/p75) was first identified as an 
interaction partner of HIV-1 IN by coimmunoprecipitation experiments in human 
cells expressing IN from a synthetic gene (Cherepanov et al., 2003). Independent 
screens exploiting the same method (Turlure et al., 2004) and subsequent use of 
the yeast two-hybrid assay (Emiliani et al., 2005) confirmed this result. 
LEDGF/p75 is a ubiquitously expressed chromatin-associated protein that is 
thought to normally function in transcriptional regulation, stress response and 
apoptosis pathways (Ganapathy et al., 2003). 
LEDGF/p75 is a multidomain protein (Figure 6), which not only comprises an IN 
binding domain (IBD) situated C-terminally (Cherepanov et al., 2004; Vanegas et 
al., 2005), but also several motifs involved in DNA and chromatin association 
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(Llano et al., 2006b). These include a NLS, two AT-hook elements (so named for 
their preferential binding to AT-rich DNA), and a PWWP motif that mediates 
chromatin binding (Llano et al., 2006b; Turlure et al., 2006). 
 
Figure 6. LEDGF/p75 domain organization. (Vandegraaff and Engelman, 2007). 
Upon ectopic expression, HIV-1 IN localizes to the nucleus and tightly binds to 
mitotic chromosomes (Cherepanov et al., 2000; Devroe et al., 2003), properties 
that can be attributed to its interaction with endogenous LEDGF/p75. In fact, RNAi-
mediated knockdown of LEDGF/p75 results in the disruption of IN nuclear 
localization, redistributing the vast majority of the protein to the cytoplasm 
(Maertens et al., 2003) (Llano et al., 2004b). Moreover, a mutant IN form, with 
reduced binding affinity to LEDGF/p75 in vitro, fails to interact with chromosomes 
(Emiliani et al., 2005). Based on these results, a possible role for LEDGF/p75 in 
chromosomal tethering of HIV-1 PICs has been proposed. 
Initial studies on the effect of LEDGF/p75 depletion on HIV-1 infectivity produced 
conflicting and inconsistent results (Llano et al., 2004b) (Vandegraaff et al., 2006) 
(Vandekerckhove et al., 2006). However, more complete knockdowns, which were 
able to eradicate detectable LEDGF/p75 from chromatin, or the use of mouse 
embryo fibroblasts (MEFs) derived from LEDGF/p75 knockout mice, revealed a 
significant loss in HIV-1 infectivity in the absence of this cellular factor (Llano et al., 
2006a; Shun et al., 2007b). Consistently, overexpression of LEDGF/p75 IBD, which 
competes with the endogenous protein for the interaction with IN but is unable to 
interact with chromatin, imposes a severe defect in HIV-1 infectivity (De Rijck et al., 
2006). The defect imposed by both LEDGF/p75 depletion and LEDGF/p75 IBD 
overexpression specifically occurs at the step of integration (Llano et al., 2006a) 
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(De Rijck et al., 2006). Taken together, these results highlighted an essential role 
for the interaction between IN and LEDGF/p75 during the HIV-1 replication cycle, 
suggesting that this interaction might function by docking the PICs to chromatin. 
Given its proposed role in the tethering of HIV-1 PICs to chromatin, the hypothesis 
was made that LEDGF/p75 could potentially function in integration target site 
selection. Indeed, analysis of the integration site distribution in human cells 
depleted of LEDGF/p75 by RNAi or in MEFs derived from LEDGF/p75 knockout 
mice revealed that the residual integration, which can still be found in these cells, is 
reduced in TUs (Ciuffi et al., 2005; Marshall et al., 2007; Shun et al., 2007b). 
Furthermore, analysis of the GC content of HIV-1 integration sites in LEDGF/p75-
expressing cells indicated that AT-rich regions are favored for integration than GC-
rich regions, consistently with the presence of an AT-hook motif in LEDGF/p75. 
Thus, LEDGF/p75 binding to AT-rich sites appears to direct integration into these 
sequences. Another approach to investigate the role of LEDGF/p75 in HIV-1 
integration site selection examined the frequency of integration events in 
LEDGF/p75-modulated genes. Since LEDGF/p75 modulates gene expression by 
binding to DNA, LEDGF/p75-regulated genes should have more bound LEDGF/p75 
than randomly selected genes, and thus be preferential integration targets. As 
expected, LEDGF/p75-modulated genes proved to be favored targets in cells 
expressing LEDGF/p75, while this preference was abolished in LEDGF/p75 
depleted cells (Ciuffi et al., 2005). These data collectively suggested a role for 
LEDGF/p75 in promoting HIV-1 DNA integration in TUs and AT-rich regions, thus 
providing the first example of an apparent tethering protein for retroviral integration. 
Recently, the tethering model for Ledgf/p75 function was strengthened by the 
finding that expression of fusion proteins containing the IBD of Ledgf/p75 fused to 
alternative chromatin binding domains in LEDGF/p75-depleted cells redirects viral 
DNA integration to sites in the genome that reflect the chromatin binding patterns 
of the chimeric protein (Ferris et al., 2010; Gijsbers et al., 2010; Silvers et al., 
2010). 
The demonstrated importance of the association between IN and LEDGF/p75 in 
HIV-1 integration raised the possibility that this interaction could be exploited as an 
antiviral target. The proof-of-concept of the feasibility of this approach was provided 
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by the overexpression of the LEDGF/p75 IBD in human cells (De Rijck et al., 
2006). In fact, this LEDGF/p75 fragment lacking the chromatin-binding domain 
proved able to efficiently compete with the endogenous cofactor, thus inhibiting 
HIV-1 replication and integration to nearly undetectable levels (De Rijck et al., 
2006). Moreover, resistance to the LEDGF/p75 IBD fragment arose during virus 
passaging; this resistance was conferred by mutations in IN mapping to the IN/IBD 
binding interface. Notably, replication of the IBD-resistant virus was even more 
sensitive to LEDGF/p75 depletion than was that of the wild-type virus, indicating 
that the resistant mutant did not replicate in a LEDGF/p75-independent manner 
(Hombrouck et al., 2007). The development of small molecules that specifically 
disrupt the interaction between IN and LEDGF/p75 to block HIV-1 replication will be 
discussed in the following section. 
TRN-SR2 
The cellular protein transportin-SR2 (TRN-SR2, TNPO3, transportin 3) was 
recently identified as a cofactor of HIV-1 replication, which is required for nuclear 
import of the PIC both in cycling cell lines and in macrophages (Brass et al., 2008; 
Christ et al., 2008; Konig et al., 2008). TRN-SR2 is an importin-β-like karyopherin 
that plays the role of transporter of serine/arginine-rich splicing factors (SR 
proteins) into the nucleus (Kataoka et al., 1999). TRN-SR2 was also identified as a 
binding partner of HIV-1 IN by yeast two-hybrid screenings using IN as a bait, and 
rebound screenings using a HIV-1 library confirmed that TRN-SR2 interacts solely 
with IN and none of the others viral proteins (Christ et al., 2008; Rain et al., 2009). 
It was therefore proposed that TRN-SR2 mediates nuclear import of the HIV-1 PIC 
through the interaction with IN. However, whereas a direct interaction between 
HIV-1 IN and TRN-SR2 was confirmed by different studies (Christ et al., 2008; 
Krishnan et al.; Rain et al., 2009), its role during the PIC nuclear import is currently 
under debate. Given that MLV replication is independent of TRN-SR2 expression 
(Christ et al., 2008), the finding that a chimeric HIV/MLV clone carrying MLV CA is 
insensitive to TRN-SR2 knockdown (Krishnan et al., 2010), together with the 
identification of a HIV-1 clone bearing the N74D mutation in CA whose replication 
is not affected by TRN-SR2 depletion (Zhou et al., 2011), led to the hypothesis that 
the TRN-SR2 dependency of HIV-1 nuclear import is mediated by CA rather than 
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IN, although no evidence was provided that TRN-SR2 and CA physically interact. A 
subsequent report provided a potential explanation for the phenotype of the N74D 
CA mutant HIV-1 clone, showing that the mutant virus was insensitive to TRN-SR2 
depletion only when pseudotyped with VSV-G, while the same mutant clone 
proved to be still dependent on TRN-SR2, although to a somewhat lesser extent, 
when retaining the HIV-1 envelope (Thys et al., 2011). It was therefore concluded 
that, while HIV-1 CA appears to modulate the nuclear entry of VSV-G pseudotyped 
viruses, its role in the nuclear import of viruses which retain their natural envelopes 
is less clear: CA may exert an indirect effect on the process of nuclear import, 
probably through its involvement in the steps of uncoating, trafficking and docking 
of the PICs to the nuclear pore, which all precede the interaction between IN and 
TRN-SR2 (Thys et al., 2011). However, a recent study aimed at assessing the role 
of the interaction between IN and TRN-SR2 during HIV-1 infection found that IN 
mutations disrupting the association with TRN-SR2, while impairing HIV-1 
replication, do not significantly affect the amounts of 2-LTR circles formed in the 
nucleus of the target cells (Cribier et al., 2011). According to the authors, the lack 
of correlation between a defect in TRN-SR2 binding by IN and the formation of 2-
LTR circles in the nucleus strongly supports the notion that the interaction between 
the two proteins is not directly involved in the nuclear import step of the viral 
replication cycle (Cribier et al., 2011). This latter study also raises the hypothesis 
that a direct interaction between IN and TRN-SR2 may take place after the entry of 
the PIC in the nucleus and proposes a model in which, beside its role in nuclear 
import, TRN-SR2 may additionally be involved in the nuclear events of HIV-1 
replication. Indeed, another report recently proposed a role for TRN-SR2, together 
with NUP358/RanBP2, in regulating the passage of the PIC through the nuclear 
pore, so as to place the complex in gene-dense regions of the genome (Ocwieja et 
al., 2011), a process that may require a direct interaction between IN and TRN-
SR2. Therefore, at present, both the mechanism of TRN-SR2-mediated nuclear 
import of HIV-1 PICs and the role played by the interaction between IN and TRN-
SR2 during the viral replication cycle still await further clarification. 
p300 
p300, a HAT enzyme acting as a transcriptional coactivator (Fukuda et al., 2006), 
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was found to interact with HIV-1 IN both in vitro and in vivo, resulting in the 
acetylation of three lysine residues, located at positions 264, 266 and 273 in the 
CTD of the viral protein (Cereseto et al., 2005; Topper et al., 2007). Interestingly, a 
mutant IN carrying arginine substitutions at these residues also proved to be 
acetylated in vivo, thus suggesting that cellular HATs other than p300 might 
acetylate IN at different sites. Acetylation by p300 was shown to increase IN 
binding affinity to DNA and enhance its strand transfer activity in vitro (Cereseto et 
al., 2005). The role of IN acetylation at lysines 264, 266 and 273 during HIV-1 
replication has been debated. One study first reported a severe replication 
impairment for a HIV-1 clone expressing the triple mutant Flag-tagged IN (Flag-IN 
K264,266,273R), due to a specific block at the step of integration (Cereseto et al., 
2005). However, the results presented in a subsequent report, while confirming the 
acetylation of IN CTD by p300 in vitro, found no effect on viral replication when 
arginine substitutions were intoduced at the p300-targeted lysine positions of IN 
(Topper et al., 2007). The discrepancy was explained by noting that the earlier in 
vivo experiments were performed with a HIV-1 clone encoding a Flag-tag epitope 
fused downstream and in frame with the C-terminus of IN. Subsequently, in the 
context of a study aimed at developing HIV-based non-integrating lentiviral vectors 
(NILVs) as gene therapy tools, the integration efficiency of a GFP-expressing 
vector harboring mutations at IN lysines acetylated by p300 was determined 
(Apolonia et al., 2007). The IN K264,266,273R mutant vector exhibited a five-fold 
lower GFP expression level than the vector encoding wild type IN, which was 
paralleled by a fourteen-fold lower residual integration rate. The overall importance 
of IN CTD acetylation by p300 to HIV-1 integration and replication therefore awaits 
further clarification. For sure, given the observed in vivo acetylation of the IN triple 
mutant, an interesting issue for the future would be to determine whether additional 
IN lysines are targets for acetylation by HATs different from p300 and whether IN is 
subject to other post-translational modifications by as-yet-unidentified cellular 
cofactors. 
Post-translational modifications of IN 
HIV-1 IN is subject to several post-translational modifications that contribute to 
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modulate its activities. 
The intracellular stability of IN is regulated through polyubiquitination and 
subsequent proteasome-dependent degradation (Devroe et al., 2003; Emiliani et 
al., 2005; Llano et al., 2004a; Mulder and Muesing, 2000; Tasaki et al., 2005). 
Notably, the IN cellular binding partners LEDGF/p75 (Llano et al., 2004a), hRad18 
(Mulder et al., 2002) and Ku70 (Zheng et al., 2011) have all been reported to 
protect the viral protein from the host ubiquitin-proteasome system during HIV-1 
replication. 
Modulation of the efficiency of integration can be achieved through the reversible 
acetylation of IN, which has been found to enhance its strand transfer activity in 
vitro (Cereseto et al., 2005; Terreni et al.). Consistently, arginine substitutions 
introduced at the IN lysines targeted by acetylation have been shown to negatively 
affect the infectivity of the mutant viruses by specifically reducing their integration 
level (Cereseto et al., 2005; Terreni et al.). 
SUMOylation of IN may also contribute to regulate the efficiency of HIV-1 
integration. In fact, it has been recently reported that IN is SUMOylated and the 
functional relevance of this post-translational modification has been highlighted by 
the finding that mutant viruses harboring a SUMOylation-defective IN are less 
infectious than their wild-type counterparts (Zamborlini et al., 2011). However, 
differently from acetylation, SUMOylation of IN does not seem to affect the catalytic 
activity of the protein, since SUMOylation-defective IN mutants still retain wild-type 
levels of enzymatic activity. Therefore, the possibility is currently being explored 
that SUMOylation may regulate the binding affinity of IN to cofactors required for 
the efficient completion of the viral replication cycle. 
Finally, IN phosphorylation proved to be involved in the regulation of the 
permissiveness of resting CD4+ T cells to HIV-1 infection (Manganaro et al., 2010). 
In activated T lymphocytes, IN is phosphorylated by c-Jun N-terminal kinase (JNK), 
and then becomes a substrate for the cellular peptidyl prolyl-isomerase enzyme 
Pin1, leading to a conformational change in the viral protein (Manganaro et al., 
2010). These concerted enzymatic activities lead to increased IN stability and are 
required for efficient HIV-1 integration and infection (Manganaro et al., 2010). Since 
JNK is not expressed in resting CD4+ T cells, lack of the above-mentioned 
Introduction 
 40 
modifications likely contributes to the restriction of HIV-1 infection observed in 
these lymphocytes. 
Restriction of infection at the integration step: KAP1 
A recent study extended the family of host factors able to restrict HIV-1 infection 
through the identification of a cellular protein belonging to the TRIM family, KAP1, 
which interferes with the integration step of the viral replication cycle (Allouch and 
Cereseto, 2011). KAP1 was identified in a yeast two-hybrid screening of host 
proteins that specifically interact with the acetylated form of HIV-1 IN (Allouch and 
Cereseto, 2011). Indeed, further characterization of the association between the 
two proteins showed that KAP1 binds with higher affinity to IN upon its acetylation, 
both in vitro and in cultured cells (Allouch et al., 2011). Investigation on the role of 
KAP1 during the HIV-1 replication cycle led to the conclusion that KAP1 inhibits 
viral infectivity by specifically interfering with the integration process, as evidenced 
by the finding that KAP1 downregulation causes an increase in level of integration, 
while KAP1 overexpression results in a reduction of provirus formation (Allouch et 
al., 2011). The antiviral mechanism proposed for KAP1 consists in the recruitment 
of the histone deacetylase HDAC1 to acetylated IN, thus leading to deacetylation 
of the viral protein and consequent reduction of the integration efficiency. 
Consistently, the activity of KAP1 against HIV-1 proved to be fully dependent on 
deacetylation, as it was found to be ineffective in the absence of HDAC1, even if 
KAP1 was overexpressed (Allouch et al., 2011). However, since KAP1 is 
ubiquitously expressed showing no major restriction of HIV-1 infectivity, further 
studies are required to elucidate the strategy adopted by the virus to counteract 
this newly discovered host defense mechanism. 
IN inhibitors to treat HIV-1 infection 
The development of RT and PR inhibitors and the subsequent introduction of 
combination drug regimens enhancing the overall efficacy and durability of 
antiretroviral therapy revolutionized the treatment of HIV-1 infection in the mid 
1990’s. As the last of the three essential HIV-1 enzymes, IN was considered an 
equally attractive target for antiretroviral drug development as RT and PR, but it is 
only a decade later that the first IN inhibitor, raltegravir (RAL, MK-0518) achieved 
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approval by the US Food and Drug Administration (FDA) (reviewed in (Cahn and 
Sued, 2007)), while elvitegravir (EVG, GS-9137, JTK303) has reached phase III 
clinical trials. Both RAL and EVG are derived from the diketo acid (DKA) family of 
IN inhibitors. DKAs were the first IN inhibitors reported with selectivity for the strand 
transfer step of the integration reaction (ST-inhibitors), high specificity for IN, and 
antiviral activity that could be related to IN inhibition (Hazuda et al., 2000). Their 
selective effect on the strand transfer reaction is a direct result of a mechanism of 
action in which the inhibitor: 1) only binds to the IN catalytic site in the presence of 
a viral DNA substrate and not to IN alone (Espeseth et al., 2000) and 2) chelates 
the two essential magnesium metal ion cofactors from the IN active site, thus 
rendering the metal-dependent phosphotransferase responsible for strand transfer 
inactive (Grobler et al., 2002; Marchand et al., 2003; Pais et al., 2002). 
Despite its recent success in the clinic, emergence of resistance leading to 
treatment failure has already been reported for RAL. All the major mutations 
responsible for decreased susceptibility to RAL appear to localize within the IN 
active site proximal to the residues involved in coordinating the metal cofactors 
(Hazuda, 2010), consistent with the mechanism of inhibition based on metal 
chelation. Distinct subsets of IN mutations have been characterized in the viral 
sequences of patients who have failed the therapy with RAL. The “primary 
mutations” conferring high-level resistance to RAL have been identified as 
Q148R/H/K, N155H, and Y143R/C (Delelis et al., 2009; Kobayashi et al., 2008; 
Malet et al., 2009; Malet et al., 2008; Marinello et al., 2008; Shimura et al., 2008; 
Sichtig et al., 2009). Each tends to be associated with “secondary mutations” that 
appear to restore viral fitness in those primary mutants: for instance, the secondary 
mutation E92Q invariably clusters with the N155H mutation, while the G140S is 
mainly found in the Q148H mutants (Cooper et al., 2008; Delelis et al., 2009; Malet 
et al., 2009). The resistance profile of EVG closely resembles that of RAL, 
suggesting that EVG is unlikely to overcome resistance to RAL (Marinello et al., 
2008). Current research efforts are therefore devoted to the discovery and 
development of novel compounds effective against viral strains resistant to IN ST-
inhibitors. A promising approach that is currently being explored is that of targeting 
for antiviral therapy the interactions between IN and cellular cofactors, if 
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demonstrated to be essential for HIV-1 infection. In particular, the LEDGF/p75-IN 
interaction proved to be an attractive therapeutic target, since the crucial role of this 
cellular cofactor in HIV-1 replication was evidenced via mutagenesis, RNAi, 
transdominant overexpression of LEDGF/p75 IBD and knockout studies 
(Busschots et al., 2007; Cherepanov et al., 2003; De Rijck et al., 2006; Emiliani et 
al., 2005; Hombrouck et al., 2007; Llano et al., 2006a; Shun et al., 2007b; 
Vandekerckhove et al., 2006). Determination of the co-crystal structure of the 
LEDGF/p75 IBD bound to the IN CCD (Cherepanov et al., 2005) allowed structure-
based drug design of a series of 2-(quinolin-3-yl)acetic acid derivatives that act as 
potent inhibitors of the LEDGF/p75-IN interaction and are known under the name 
of LEDGINs (which stands for LEDGF/p75-integrase inhibitors). LEDGINs were 
shown to inhibit HIV-1 replication by specifically blocking the integration step both 
in cultured cell lines and in peripheral blood lymphocytes from human donors. Most 
importantly, LEDGINs proved to remain fully active against viral strains resistant to 
IN ST-inhibitors, clearly demonstrating their different mode of action (Christ et al., 
2010; Debyser and Christ, 2010). Based on the co-crystal structures determined for 
multiple LEDGINs in complex with the IN CCD, the initial compounds were 
optimized, leading to the development of molecules that exhibit potencies in the 
low nanomolar range and reduced toxicity in cell culture. Of note, these optimized 
LEDGIN compounds show a selectivity index, which is a measure for lack of 
cellular toxicity but potent antiviral activity, comparable to that of antiviral drugs 
currently used in the clinic (Debyser and Christ, 2010). Therefore, since LEDGINs 
are effective IN inhibitors that do not show any cross-resistance with ST-inhibitors, 
they have significant clinical potential as second-generation IN inhibitors. 
Finally, another approach to inhibit HIV-1 IN function that is currently the object of 
intense research is the development of small molecules that can interfere with IN 
catalytic activity through allosteric modulation of the dynamic interaction existing 
between its monomeric, dimeric and tetrameric forms. The development of an 
assay for the screening of modulators of HIV-1 IN dimerization has recently 
allowed the identification of compounds that act as allosteric IN inhibitors 
(Demeulemeester et al., 2012). As a consequence of the strict correlation between 
IN catalytic activity and its specific oligomeric forms, these newly identified 
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modulators of the IN oligomerization equilibrium represent the first step towards an 
as-yet-unexplored promising antiviral strategy. 
Acetylation 
Post-translational modification (PTM) of proteins extends the range of possible 
molecular structures beyond the limits imposed by the twenty encoded amino acids 
and, if reversible, gives a means of control and signaling. Lysine acetylation 
consists in the transfer of an acetyl group from acetyl-coenzyme A (acetyl-CoA) to 
the ε-amino group of a specific lysine residue in the target protein. Lysine 
acetylation was first discovered with histones in 1968 (Gershey et al., 1968), but 
the responsible enzymes, histone acetyltransferases (HATs) and deacetylases 
(HDACs), were not identified until the mid-1990s (Bannister and Kouzarides, 1996; 
Brownell and Allis, 1995; Brownell et al., 1996; Kleff et al., 1995; Mizzen et al., 
1996; Ogryzko et al., 1996; Parthun et al., 1996; Rundlett et al., 1996; Taunton et 
al., 1996; Yang et al., 1996a; Yang et al., 1996b). In the past decades, knowledge 
about this PTM has exploded, with targets rapidly expanding from histones to a 
wide variety of proteins of both cellular and viral origin (Caron et al., 2003; Cohen 
and Yao, 2004; Kouzarides, 2000; Sterner and Berger, 2000; Yang and Gregoire, 
2007). 
The diversity of HATs 
According to sequence similarities, known HATs can be organized into different 
groups. Of the reported HAT families, the GNAT (GCN5-related N-
acetyltransferase), MYST (MOZ, Ybf2, Sas2 and Tip60) and p300/CBP (Creb-
binding protein) families are the best characterized, both structurally and 
functionally (Lee and Workman, 2007; Roth et al., 2001; Sterner and Berger, 
2000). 
GNAT family members include the highly homologous HATs GCN5 (general 
control nonderepressible 5) and PCAF (p300/CBP associated factor), as well as 
other more distantly related enzymes. GCN5 and PCAF appear to primarily 
function as histone-acetylating transcriptional coactivators (Carrozza et al., 2003; 
Nakatani, 2001; Roth et al., 2001), but also catalyze the acetylation of non-histone 
substrates, leading to changes in their activities (Glozak et al., 2005; Kouzarides, 
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2000; Polevoda and Sherman, 2002; Sterner and Berger, 2000). 
p300 and CBP form a pair of paralogous transcriptional coactivators possessing 
intrinsic HAT activity (Bannister and Kouzarides, 1996; Ogryzko et al., 1996). Since 
these two proteins seem to be largely interchangeable in function, at least in 
cultured cells (Arany et al., 1995; Eckner et al., 1994; Lundblad et al., 1995; 
Shiama, 1997), they are commonly referred to as p300/CBP. Like PCAF and 
GCN5, p300/CBP is also known to acetylate and regulate various protein 
substrates other than histones (Glozak et al., 2005; Kouzarides, 2000; Polevoda 
and Sherman, 2002; Sterner and Berger, 2000). 
The MYST family of proteins constitutes a third major group of HATs. The acronym 
MYST derives from its four founding members: human MOZ (monocytic leukemia 
zinc finger protein) (Borrow et al., 1996), yeast Ybf2/Sas3 (Reifsnyder et al., 1996; 
Takechi and Nakayama, 1999), yeast Sas2 (Reifsnyder et al., 1996) and 
mammalian Tip60 (HIV-1 Tat interacting 60 kDa protein) (Kamine et al., 1996; Ran 
and Pereira-Smith, 2000; Yamamoto and Horikoshi, 1997). As compared with the 
GCN5/PCAF and p300/CBP groups, the MYST family is larger and more 
heterogeneous in domain organization and biological function (Yang, 2004b). 
Most HATs have been found within large multiprotein complexes in vivo. 
Importantly, these enzymes, upon incorporation into such complexes, often change 
their substrate specificities (Boudreault et al., 2003; Grant et al., 1997; Ogryzko et 
al., 1998; Sendra et al., 2000), suggesting that associated components regulate 
the activities of the respective catalytic subunits. Amazingly, one HAT can be the 
catalytic subunit of multiple complexes. For instance, metazoan GCN5 participates 
in the constitution of at least two distinct types of multiprotein complexes (Nagy and 
Tora, 2007), as will be furtherly discussed in the “Metazoan GCN5-containing 
complexes” section. 
HDACs 
Fortuitously, the same year that the first HATs were identified, the first HDAC, 
catalyzing the removal of acetyl groups from the N-terminal tails of nucleosomal 
histones, was also discovered (Taunton et al., 1996). Remarkably, this mammalian 
HDAC was homologous to the yeast transcriptional corepressor Rpd3p. In the 
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subsequent years, more corepressors were recognized to be HDACs, just as more 
coactivators were identified as HATs, providing strong support for the notion that 
hyperacetylated chromatin is transcriptionally active, while hypoacetylated 
chromatin is repressed. 
Similarly to HATs, HDACs also occur in multiprotein complexes, which are 
recruited by DNA-binding factors to direct local transcriptional repression through 
histone deacetylation. In addition to histones, HDACs also deacetylate a variety of 
different substrates, including transcription factors and other cellular proteins, 
involved in the control of cell growth, differentiation and apoptosis (Glozak and 
Seto, 2007). 
Aberrant activity of HDACs is well known to be associated with oncogenesis in 
humans, since it can lead to the suppression of the expression of various tumour 
suppressor genes (Cress and Seto, 2000; Timmermann et al., 2001), and 
numerous clinical trials involving HDAC inhibitors (HDACi) have been successfully 
conducted for the treatment of both haematological and solid tumours (Stimson et 
al., 2009). 
Histone acetylation in the regulation of gene expression 
Histones are extensively modified by a myriad of reactions; examples include 
acetylation, methylation, ubiquitination, SUMOylation, phosphorylation, and ADP-
ribosylation. These modifications alter chromatin dynamics by influencing histone-
DNA interactions, as well as the recruitment and binding of protein factors to 
chromatin (reviewed in (Taverna et al., 2007)). The tight correlation between 
histone modification patterns and their subsequent regulation of chromatin activity 
led to the hypothesis that PTM of histones encodes a language, the so-called 
“histone code”, that is read by chromatin-interacting proteins to bring about distinct 
downstream events crucial for both short- and long-term regulation of 
transcriptional activity (Strahl and Allis, 2000). These chromatin-binding proteins 
interact with chromatin through several distinct domains, each of which has the 
ability to recognize different histone modifications and can be responsible for the 
targeting of multisubunit protein complexes to specific chromatin regions. 
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Histone acetylation is a PTM that performs two known functions on chromatin. 
First, acetylation neutralizes the positive charge of lysine residues within the 
histone tails, thus reducing their ability to form electrostatic interactions with the 
negatively charged phosphodiester backbone of associated DNA. The acetylation 
of histones is therefore associated with chromatin decondensation, which results in 
an increased accessibility of transcription factors to their target sequences on DNA 
(Lee et al., 1993; Nightingale et al., 1998; Vettese-Dadey et al., 1996). The second 
known function of histone acetylation is to provide a platform for the recruitment of 
transcriptional regulatory proteins through acetyl-lysine interacting motifs, known as 
bromodomains (Dhalluin et al., 1999) (Jacobson et al., 2000). 
Bromodomain structure and function 
The bromodomain, found in HATs and chromatin-associated proteins, functions as 
the sole protein module known to bind acetyl-lysine motifs. Consistent with the 
reversible nature of lysine acetylation, the bromodomain/acetyl-lysine interaction is 
dynamic and likely transient in the cells. This notion is supported by the three-
dimensional structure of the bromodomain, as first revealed with that of the human 
PCAF bromodomain (Dhalluin et al., 1999). Since then, a number of three-
dimensional structures of bromodomains, either in the free form or bound to an 
acetyl-lysine containing peptide have been reported in literature, including those 
from human and yeast GCN5 (Hudson et al., 2000; Owen et al., 2000), human 
CBP (Mujtaba et al., 2004) and human SWI/SNF chromatin remodeling complex 
protein Brg1 (Brahma-related gene 1) (Shen et al., 2007). These structures, 
determined either in solution or crystalline state, confirmed the early prediction from 
the first bromodomain structure (Dhalluin et al., 1999), which is that most, if not all, 
bromodomains adopt a distinct structural fold, termed the “BRD fold”, consisting of 
a left-handed bundle of four helices (αZ, αA, αB, αC), with the inter-helical ZA and 
BC loops of variable length and sequence, and that the latter loops constitute a 
hydrophobic pocket serving for the interaction with the acetyl-lysine (Figure 7A). 
The structurally flexible ZA loop likely determines the dynamic nature of acetyl-
lysine binding. The modular nature of the BRD fold enables the bromodomain to 




Despite the structurally conserved BRD fold, the overall sequence similarity of the 
large bromodomain family is not high, with major sequence variations in the ZA and 
BC loops (Jeanmougin et al., 1997). Nevertheless, the amino acids involved in 
acetyl-lysine recognition are among the most highly conserved residues in the 
bromodomain family and correspond to Tyr-1125, Tyr-1167 and Asn-1168 in CBP 
(Figure 7B) (Mujtaba et al., 2004; Zeng et al., 2008). The crystal structure of the 
yeast GCN5 bromodomain bound to a histone H4 peptide containing acetylated 
Lys-16 showed that, in addition to binding to the conserved Tyr-364 and Tyr-406 
residues (corresponding to Tyr-1125 and Tyr-1167 in CBP, respectively), the 
acetyl-lysine residue forms a specific hydrogen-bond between the oxygen of the 
acetyl carbonyl group and the side chain amide nitrogen of the conserved 
asparagine residue, Asn-407 (corresponding to Asn-1168 in CBP) (Owen et al., 
2000). A network of water-mediated hydrogen bonds involving carbonyl groups 
from the protein backbone at the base of the binding pocket also contributes to 
acetyl-lysine binding. The critical role of these three conserved amino acid residues 
in acetyl-lysine recognition was confirmed by mutagenesis studies (Dhalluin et al., 
1999; Mujtaba et al., 2002; Mujtaba et al., 2004). The crystal structure of the yeast 
GCN5 bromodomain complexed with the histone H4-derived acetylated peptide 
also showed that the specificity for the sequence surrounding the acetyl-lysine is 
conferred by the binding of the peptide side chains at (Kac +2) and (Kac +3) 
positions, thus suggesting that the yeast GCN5 bromodomain may discriminate 
between different acetylated lysines, depending on the sequence context in which 
they are inserted. 
Roles for bromodomains in at least four functions have been recognized. First, they 
are important for stable promoter occupancy by chromatin-modifying complexes in 
the absence of the transcriptional activators, which initially recruited them. This is 
exemplified by the observation that anchoring of the yeast SAGA coactivator 
complex on acetylated chromatin for persistent acetylation requires the 
bromodomain of its catalytic subunit, GCN5 (Hassan et al., 2002). 
Second, bromodomains contribute to acetylation-dependent chromatin assembly 
and remodeling. This is evidenced by the finding that the bromodomain of 
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Swi2/Snf2, the ATPase subunit of the yeast chromatin-remodeling complex 
SWI/SNF, is required for both stable occupancy of acetylated promoter 
nucleosomes by SWI/SNF (Hassan et al., 2002) and functional activity of the 
complex on SAGA-acetylated nucleosomes (Hassan et al., 2006). 
Third, bromodomains are involved in organizing chromosome or chromatin 
domains. Compared to nucleosome assembly and remodeling, this is a large-scale 
and long-range effect. For instance, Bdf1 (bromodomain factor 1) is a yeast protein 
containing two bromodomains, which, by binding to acetylated histone H4, is able 
to impose a physical barrier between euchromatin and heterochromatin, thus 
preventing heterochromatic spreading (Ladurner et al., 2003; Matangkasombut and 
Buratowski, 2003). Similarly to Bdf1, several mammalian bromodomain containing 
(Brd) proteins have been reported to exhibit acetylation-dependent binding to 
chromatin (Dey et al., 2003; Kanno et al., 2004; Peng et al., 2006; Pivot-Pajot et 
al., 2003), suggesting that proteins belonging to the Brd family may contribute to 
the translation of the so-called histone code (Crowley et al., 2002; Dey et al., 2003; 
Dey et al., 2000; Mattsson et al., 2002). 
Fourth, bromodomains also recognize acetylated non-histone proteins, of both 
cellular and viral origin. Thus, bromodomain/acetyl-lysine interaction plays a direct 
role in mediating the consequential functions arising from acetylation of these 
proteins. For instance, transcriptional activation of HIV-1 proviral DNA is dependent 
on a molecular interaction between acetylated Tat and the bromodomain of the 
cellular coactivator PCAF (Dorr et al., 2002; Mujtaba et al., 2002). Again, human 
p53 transcriptional activity requires the binding of its C-terminal acetylated lysine 
382 to the bromodomain of the coactivator CBP. This bromodomain/acetyl-lysine 
binding is responsible for p53 acetylation-dependent coactivator recruitment after 
DNA damage, a step essential for p53-induced transcriptional activation of its 
target genes, such as p21 (Mujtaba et al., 2004; Sachchidanand et al., 2006). 
In conclusion, at present, available data are all consistent with the notion of the 
bromodomain being a protein module that can specifically process molecular 




Figure 7. Structural basis of acetyl-lysine recognition by the bromodomain. (A) The 3D structure 
of the CBP bromodomain bound to a H4-K20ac peptide; and (B) the acetyl-lysine binding site, showing 
the key interactions between the CBP bromodomain and the H4-K20ac peptide. The peptide is yellow 
and the side chains of the protein residues are color-coded by atom type. (Sanchez and Zhou, 2009). 
Acetylation of non-histone proteins 
In addition to histones, HATs can also target non-histone substrates, such as 
transcription factors and other nuclear proteins, as well as structural components, 
metabolic enzymes and signalling regulators in the cytoplasm (Yang and Seto, 
2007). Moreover, several viruses have been recently found to encode specific 
proteins that are substrates for cellular HATs. Acetylation has been reported to 
regulate the activity of target proteins by modulating DNA binding (Gu and Roeder, 
1997; Marzio et al., 2000; Yao et al., 2001), interaction with partners (Bannister et 
al., 2000; Cohen et al., 2004; Kovacs et al., 2005; Yuan et al., 2005), subcellular 
localization (Blander et al., 2002; Kawaguchi et al., 2006; Kitamura et al., 2005; 
Thevenet et al., 2004) and stability (Bernassola et al., 2004; Jeong et al., 2002; Li 
et al., 2002). Protein acetylation is therefore emerging as an important signaling 
pathway involved in the control of both cellular and viral functions. 
HAT autoacetylation 
Reminiscent of kinase autophosphorylation, HATs themselves are acetylated. 
Prominent examples are represented by p300 and CBP, which are heavily 
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autoacetylated in an intermolecular fashion (Karanam et al., 2006), suggesting that 
dimerization may trigger autoacetylation. An attractive model proposes that DNA-
binding proteins may recruit p300 and bring two or more p300 molecules into 
physical proximity, leading to intermolecular acetylation and consequent enzymatic 
activation. Consistent with this hypothesis, many transcription factors are able to 
stimulate the HAT activity of p300 and CBP, and the recruitment to DNA also 
seems to be important for p300 activation (Dornan et al., 2003). 
Acetylation of trancription factors 
A decade ago, HATs were first reported to acetylate the tumour suppressor and 
transcription factor p53, leading to the notion that HATs and HDACs are not 
specific to histones (Gu and Roeder, 1997). Since then, several transcription 
factors have been identified as substrates for HATs, including E2F (involved in the 
progression through the G1/S checkpoint) (Martinez-Balbas et al., 2000; Marzio et 
al., 2000), c-Jun (participating in the response to mitogens) (Vries et al., 2001), the 
erythroid Kruppel-like transcription factor (EKLF) (Zhang and Bieker, 1998; Zhang 
et al., 2001), the transcriptional coactivator GATA1, which is required for 
megakaryocyte and erythrocyte differentiation (Boyes et al., 1998), the muscle-
specific differentiation regulator MyoD (Polesskaya et al., 2000; Sartorelli et al., 
1999) and the oncoprotein c-Myc (Patel et al., 2004). Acetylation of trancription 
factors can alter their ability to bind DNA. For p53, E2F1, and GATA1, acetylation 
stimulates their sequence-specific DNA binding activity, consequently resulting in 
an increased activation of their target genes (Boyes et al., 1998; Gu and Roeder, 
1997; Martinez-Balbas et al., 2000). Acetylation can also affect protein-protein 
interactions, forming docking sites for the recruitment of transcriptional 
coactivators. For instance, acetylation at lysine 382 increases p53 affinity for the 
bromodomain of CBP (Mujtaba et al., 2004), while acetylation of lysines 373 and 
382 promotes the interaction with the tandem bromodomains of TAF1, a subunit of 
the basal transcription factor TFIID (Li et al., 2007). Similarly, MyoD acetylation 
triggers the recognition of the acetylated residues by the bromodomain of CBP, 
thus strengthening the interaction between the HAT and MyoD itself (Polesskaya et 
al., 2001). This event finally results in a more efficient recruitment of HAT 
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complexes to muscle-specific promoters, where they acetylate other substrates 
such as histones (Polesskaya et al., 2001). In addition, acetylation increases the 
half-life of p53 by preventing its Mdm2-mediated ubiquitination and subsequent 
degradation (Li et al., 2002). Since the lysines ubiquitinated by MDM2 are the 
same residues targeted for acetylation after DNA damage, acetylation of these 
lysines is believed to prevent ubiquitination at the same sites, leading to p53 
stabilization (Li et al., 2002). Finally, acetylation is involved in the control of the 
nucleocytoplasmic shuttling of various transcription factors. For instance, the 
nuclear action of NF-κB (a heterodimer of RelA and p50 proteins) is controlled by 
regulating its interaction with the IκBα inhibitor, which normally binds and 
sequesters the transcription factor in the cytoplasm. Acetylation of the RelA subunit 
of NF-κB results in the disruption of the inhibitory interaction with IκBα  (Chen et al., 
2001). Acetylated RelA is subsequently deacetylated, promoting effective binding 
to IκBα and leading to IκBα-dependent nuclear export of the complex (Chen et al., 
2001). Deacetylation of RelA thus acts as an intranuclear molecular switch that 
both controls the duration of the NF-κB transcriptional response and contributes to 
the replenishment of the depleted cytoplasmic pool of inactive NF-κB/IκBα 
complexes. 
Acetylation of HMG proteins 
The high mobility group (HMG) proteins are abundant and ubiquitous nuclear 
proteins that bind to DNA, nucleosomes and other multiprotein complexes in a 
dynamic and reversible fashion to regulate DNA processing in the context of 
chromatin. Three distinct families of HMG proteins have been defined, including 
HMG-AT-hook (HMGA), HMG-box (HMGB) and HMG-nucleosome binding 
(HMGN) families (Bustin, 2001b). 
The ordered acetylation of lysine residues in the HMGA1a protein governs the 
accurate execution of the interferon-β gene transcriptional switch (Munshi et al., 
2001). CBP and PCAF are both able to acetylate HMGA1a (Munshi et al., 2001; 
Munshi et al., 1998). However, the acetylation mediated by these two enzymes has 
opposite biological outcomes: CBP-acetylated HMGA1a destabilizes the 
enhanceosome, a higher-order nucleoprotein complex formed in response to viral 
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infection, while PCAF-induced acetylation potentiates the gene transcription of 
interferon-β by stabilizing the enhanceosome and preventing HMGA1a from CBP-
mediated acetylation. 
Although the PTMs of HMGB proteins have not been investigated as extensively 
as those of HMGA1 proteins, growing evidence indicates the remarkable biological 
significance of HMGB acetylation. Acetylated HMGB1, isolated from cells grown in 
the presence of the HDACi butyrate, exhibits a significantly enhanced ability to 
recognize ultraviolet (UV) light- or cisplatin-damaged DNA and four-way junctions 
(Ugrinova et al., 2001), thus suggesting a critical role for acetylation in structure-
specific DNA binding by HMGB1 and its potential function in DNA repair. In 
addition, although HMGB1 localization is predominantly nuclear, it was shown that 
this protein can be either passively leaked out of cells during necrosis (Scaffidi et 
al., 2002), or secreted by monocytes and macrophages (Muller et al., 2001). A 
related study reported that, in the latter cell types, HMGB1 relocation from the 
nucleus to the cytoplasm and its subsequent secretion are dependent on the 
acetylation state of the protein (Bonaldi et al., 2003). 
HMGN proteins are the only nuclear proteins that specifically recognize the 
nucleosomal core particle (Bustin et al., 1990; Sandeen et al., 1980) and are 
present in the nuclei of all mammalian and most vertebrate cells (Bustin, 1999). 
The enzymes responsible for acetylation of HMGN proteins are p300 and PCAF 
(Bergel et al., 2000; Bustin, 2001a; Herrera et al., 1999). The main consequence of 
both p300- and PCAF-mediated acetylation of HMGN proteins is the reduction of 
their binding affinity affinity to nucleosomes (Bergel et al., 2000; Herrera et al., 
1999). 
Acetylation of nuclear import factors 
HATs also target nuclear proteins other than transcription factors. A screen of a 
large set of proteins involved in different cellular processes resulted in the 
identification of importin α, an adaptor protein involved in nuclear import, as a 
substrate for p300/CBP-mediated acetylation (Bannister et al., 2000). Importin α is 
acetylated on a single lysine residue, located at position 22. Acetylation has been 
found to promote the interaction of importin α with importin β in vitro (Bannister et 
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al., 2000), which is required for the transport of the bound cargo through the 
nuclear pore complex. Acetylation of importin α by p300 is also critical for the 
nuclear import of HuR, a shuttling RNA binding protein that plays an important role 
in regulating mRNA stability. Consistently, mutation of lysine 22 to arginine results 
in the impairment of HuR nuclear import (Wang et al., 2004). Taken together, these 
findings highlight protein acetylation as a mechanism involved in the regulation of 
nuclear import. 
Acetylation of non-nuclear proteins: α-tubulin and cortactin 
acetylation 
Microtubules are cylindrical cytoskeletal structures found in almost all eukaryotic 
cell types and involved in a great variety of cellular processes, including mitosis, 
ciliary and flagellar motility, intracellular transport of vesicles and organelles, and 
possibly in determining the morphology of certain cells (Luduena, 1998). The 
structural subunit of microtubules is the 100 kDa tubulin protein, which exists in the 
α and β isoforms that form heterodimeric complexes. Several types of PTMs have 
been found to affect tubulin function, including acetylation, phosphorylation, 
polyglutamation, polyglycylation, and detyrosination (MacRae, 1997). Acetylation is 
unique among the known tubulin modifications in that it occurs at lysine 40 of α-
tubulin, which is predicted to reside on the luminal face of microtubules. Therefore, 
it is unclear how the acetylating/deacetylating enzymes would have access to this 
site. It is also unclear how this luminal modification might influence microtubule-
based functions occurring on the cytoplasmic face of the microtubule. The 
acetylating enzymes have not been identified, but two enzymes have been shown 
to deacetylate α-tubulin both in vitro and in vivo, namely HDAC6 and Sirt2 (Hubbert 
et al., 2002; Matsuyama et al., 2002). Acetylation of α-tubulin at lysine 40 is fairly 
common and can be detected on stable microtubules in most cell types. Recent 
work has suggested that this modification plays a positive role in motor-based 
trafficking in mammals (Bulinski, 2007; Dompierre et al., 2007; Reed et al., 2006). 
Consistently, the motor protein Kinesin-1 binds with higher affinity to acetylated 
microtubules in vitro (Reed et al., 2006), and hyperacetylation of microtubules in 
neuronal cells treated with HDAC6 inhibitors causes Kinesin-1-mediated transport 
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of JIP1 to be redirected from a subset to the majority of neuritis, as well as 
enhancing the anterograde and retrograde transport of Brain Derived Nerve Factor 
(BDNF) vesicles (Dompierre et al., 2007; Reed et al., 2006). 
Acetylation of cortactin, a cytoplasmic protein involved in the regulation of cell 
motility, has been recently reported (Zhang et al., 2007). Cortactin undergoes 
acetylation at up to ten lysine residues, eight of which are located in a region of the 
protein, known as the repeat region, consisting of six and a half tandem repeats of 
a unique 37-amino acid sequence (Zhang et al., 2007). Acetylation of cortactin 
impedes its interaction with F-Actin and inhibits its translocation to the cell 
periphery, leading to aberrant cell motility. The lysines targeted for acetylation are 
separated in the primary sequence of the protein, but form two “charged patches” 
in the repeat region at the three-dimensional level. Available data indicate that 
acetylation at these sites reduces the affinity of cortactin for F-actin in a graded 
manner by altering the charge of the cortactin repeat region: once some threshold 
number of lysines becomes acetylated, the F-actin binding affinity of cortactin is 
decreased to a level that inhibits the interaction between the two proteins (Zhang et 
al., 2007). This would suggest that the acetylation of a particular lysine in the patch 
is of lesser importance than the total number of lysines that are acetylated. 
Acetylation of viral proteins 
Recent investigations revealed that several virally encoded proteins are substrates 
for acetylation by cellular HATs (Alfonso et al., 2007; Cereseto et al., 2005; Col et 
al., 2001; Kiernan et al., 1999; Madison et al., 2002; Marzio et al., 2000; Mu et al., 
2004; Ott et al., 1999; Shimazu et al., 2006; Topper et al., 2007; Xie et al., 2002; 
Zhang et al., 2000). For instance, Adenovirus E1A and HIV-1 Tat are both 
acetylated by cellular HATs, resulting in a wide variety of functional effects. The 
oncoprotein E1A is known to play a key role in the dramatic alteration of various 
essential cellular activities, leading to cell transformation and tumorigenicity 
(Gallimore and Turnell, 2001). E1A was found to be acetylated by p300/CBP and 
PCAF at a single lysine residue located at position 239 in the C-terminal domain 
(Madison et al., 2002; Zhang et al., 2000), which is involved in the interaction with 
the transcriptional corepressor C-terminal binding protein (CtBP) (Boyd et al., 
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1993). The functional outcome of E1A acetylation has been debated. One study 
showed that acetylation at lysine 239 inhibits the interaction between E1A and 
CtBP, leading to the loss of CtBP-mediated transcriptional repression and to the 
increase in the transforming potential of E1A (Zhang et al., 2000). Conversely, a 
subsequent report claimed that, rather than interfering with CtBP recruitment, 
acetylation at lysine 239 prevents the nuclear import of E1A by abrogating its 
interaction with importin 〈 (Madison et al., 2002). In such a case, acetylation may 
act to either attenuate the nuclear functions of E1A or redirect a portion of the 
protein to cytoplasmic targets. 
HIV-1 Tat can be acetylated by three different HATs at three specific lysine 
residues: lysine 28 is targeted by PCAF, while lysines 50 and 51 are substrates for 
p300/CBP and GCN5 (Col et al., 2001; Kiernan et al., 1999; Ott et al., 1999). Most 
interestingly, the acetylation of each individual lysine differently affects Tat 
functionality at the molecular level. Lysine 28 acetylation enhances the ability of 
Tat to recruit the P-TEFb complex (Kiernan et al., 1999), while modification of 
lysine 50 leads to Tat dissociation from TAR RNA (Deng et al., 2000). In addition, 
the acetylation at lysine 50, but not that at lysine 28, creates a high-affinity binding 
site for the bromodomain of PCAF (Dorr et al., 2002; Mujtaba et al., 2002). The 
accepted model explaining the role of Tat acetylation in the regulation of its activity 
is as follows (Nakatani, 2002) (Figure 8). Tat acetylated at lysine 28 would 
efficiently recruit P-TEFb and interact with TAR to enhance the processivity of RNA 
Pol II. Acetylation of Tat at lysine 50 would then help the recycling of Tat by 
inducing its release from TAR. This release seems to be promoted by the 
bromodomain of PCAF, which competes with TAR for the binding to acetylated 
lysine 50. In agreement with the proposed model, the three HATs capable of 
acetylating Tat all efficiently cooperate to stimulate transcription from the 5′ LTR of 
HIV-1 proviral DNA. In addition to Tat, the IN protein of HIV-1 has been recently 
identified as a target for acetylation by at least two different HATs, p300 and GCN5 
(Cereseto et al., 2005; Terreni et al.; Topper et al., 2007). The functional 
consequences arising from p300-mediated acetylation of IN have been previously 
discussed in the section concerning the cellular cofactors of HIV-1 integration, 





Another viral factor functionally modulated by acetylation is the Simian virus 40 
large T antigen (SV40 T-Ag), a multifunctional protein possessing cellular 
transforming activity. In this case, acetylation seems to be involved in the 
regulation of the protein stability, likely enhancing T-Ag degradation through a 
pathway independent of the ubiquitin-proteasome system (Shimazu et al., 2006). 
Acetylation has also been reported to play a role in the replication cycle of Hepatitis 
delta virus (HDV). In fact, the small hepatitis delta antigen (S-HDAg), a viral 
nucleocapsid protein essential for HDV RNA replication, can be acetylated in vitro 
at lysine 72 by the HAT domain of p300 (Mu et al., 2004). Most importantly, 
substitution of lysine 72 with arginine causes mutant S-HDAg to redistribute from 
the nucleus, where HDV replication takes place, to the cytoplasm and finally results 
in the reduction of the accumulation of HDV genomic RNA. 
The human T-cell leukemia virus type 1 (HTLV-1) transcriptional activator Tax has 
been recently identified as the target of a complex regulatory program involving 
multiple PTMs (Lodewick et al., 2009). Leukemogenesis induced by HTLV-1 has 
been linked to the ability of Tax to constitutively activate the NF-κB pathway (Chu 
et al., 1999; Harhaj and Sun, 1999; Huang et al., 2000; Kehn et al., 2004; Malek et 
al., 2001; Ratner et al., 2000; Yamamoto and Gaynor, 2004), which is known to 
depend on Tax phosphorylation, ubiquitination and sumoylation (Bex et al., 1999; 
Durkin et al., 2006; Lamsoul et al., 2005; Nasr et al., 2006; Peloponese et al., 
2004; Shembade et al., 2007; Yu et al., 2008). Another level of complexity was 
Figure 8. Acetylation signaling and Tat function. 
The acetylation of Tat K28 enhances the 
recruitment of the P-TEFb complex. The binding of 
Tat/P-TEFb to TAR RNA increases RNA Pol II 
processivity and stimulates the production of viral 
RNA transcripts. Acetylation of K50, which is in 
contact with the RNA, creates a high affinity binding 
site for the PCAF bromodomain, which then 




added to the post-translational regulation of Tax functionality by the finding that the 
nuclei of Tax-expressing cells, including HTLV-1 transformed T-lymphocytes, 
contain a pool of Tax molecules acetylated at a single lysine residue by p300 
(Lodewick et al., 2009). A functional crosstalk seems to occur between the different 
PTMs to which Tax is subjected. In fact, phosphorylation of Tax is a prerequisite for 
its localization in the nucleus and correlates with its subsequent acetylation by 
p300, whereas sumoylation, resulting in the formation of Tax nuclear bodies in 
which p300 is recruited, favors Tax acetylation (Lodewick et al., 2009). 
Overexpression of p300 markedly increases Tax acetylation and the ability of a 
wild type HTLV-1 provirus, but not of a mutant provirus encoding an acetylation 
deficient Tax protein, to activate gene expression from an integrated NF-κB-
controlled promoter (Lodewick et al., 2009). Thus, the ability of Tax to constitutively 
activate the NF-κB pathway critically depends on a hierarchical sequence of PTMs, 
which differentially controls Tax intracellular localization and its transcriptional 
activity. 
Acetylation of non-histone substrates and the protein modification 
code 
It is now clear that lysine acetylation occurs in proteins from across the nucleus to 
the plasma membrane. Acetylation patterns and the mechanistic impact vary from 
one protein to another (Glozak et al., 2005). As exemplified by the above-cited 
cases of p53 and HIV-1 Tat, the effects of acetylation can be multifaceted even for 
one protein. In general, different acetylation events can be roughly categorized into 
three groups. First, acetylation occurs at one or a few residues, and thus functions 
as a simple on/off switch. For example, acetylation of acetyl-CoA synthase (Starai 
et al., 2002) and nitric oxide synthase (Mattagajasingh et al., 2007) inactivates the 
enzymes, whereas 〈-tubulin acetylation generates a simple mark for cargo 
transport (Dompierre et al., 2007; Reed et al., 2006). Second, acetylation occurs at 
clusters of lysine residues that form “charged patches”. The number of acetylated 
residues rather than acetylation of an individual lysine seems to be important for 
the functional impact. In this case, acetylation events at different sites can have 
additive effects, thereby producing a linear output and regulating protein function in 
a quantitative manner, or provide a fail-safe mechanism. For example, cortactin is 
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acetylated at eight residues in its repeat region (Zhang et al., 2007), with each 
repeat being sufficient for F-actin binding and containing at least one lysine 
targeted by acetylation. In a third category, acetylation interacts with other PTMs 
and imparts effects in a site-specific manner. By analogy with the “histone code” 
hypothesis, a “post-translational code” model was proposed for p53, whose activity 
is regulated by numerous stress-induced PTMs (Appella and Anderson, 2000; 
Chuikov et al., 2004). Such a model has subsequently been extended to p300/CBP 
(Legube and Trouche, 2003), 〈-tubulin (Westermann and Weber, 2003), the RNA 
pol II CTD (Buratowski, 2003; Corden, 2007), nuclear receptor coregulators 
(Lonard and O'Malley B, 2007), as well as HTLV-1 Tax protein (Lodewick et al., 
2009). Conceptually, a general term like “post-translational code” can be used to 
refer to proteins with multisite PTMs. The meaning of the word “code” here is 
clearly more complicated than that in the “genetic code”, but recent studies strongly 
suggest that multisite PTMs are somewhat codified and act in sequential and 
combinatory manners (Corden, 2007; Kurash et al., 2008; Sampath et al., 2007; 
Walter et al., 2008; Winter et al., 2008). As in the case of histones (Berger, 2007), 
multisite modifications of p53 and other tightly regulated proteins form 
sophisticated programs for “intramolecular and intermolecular signaling” (Yang, 
2005). Within these programs, different PTMs interact with one another and various 
combinations yield distinct functional outcomes. Dependent on the context, lysine 
acetylation can interplay with other PTMs in an agonistic or antagonistic manner. 
The complexity of such programs in a given protein is proportional to its biological 
importance and the complexity of the corresponding organism. Therefore, lysine 
acetylation, along with other PTMs, exerts diverse cellular effects in a context-
dependent manner. 
GCN5 
The first histone-specific HAT, p55, was isolated from Tetrahymena and shown to 
be the homolog of the yeast GCN5 putative transcriptional coactivator and, thus, 
was the first enzyme to link histone acetylation and transcriptional activation 
(Brownell et al., 1996). Since then, homologs of GCN5 have been cloned and 
sequenced from numerous divergent organisms, such as human (Candau et al., 
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1996), mouse (Xu et al., 1998), and Drosophila melanogaster (Smith et al., 1998), 
suggesting that its function is highly conserved throughout the eukaryotes. 
To date, yeast GCN5 (also referred to as yGCN5) is the best characterized of the 
HATs, both structurally and functionally and both in vivo and in vitro. Various 
studies have mapped and characterized the functional domains of yGCN5 (Candau 
and Berger, 1996; Candau et al., 1997) (Figure 9). These include a C-terminal 
bromodomain, an Ada2 interaction motif and the HAT domain, which, by use of 
truncation mutants, was found to be required for the function of transcriptional 
coactivator in vivo (Candau et al., 1997). The substrate specificity of yGCN5 has 
also been investigated. In vitro, recombinant yGCN5 was shown to acetylate 
histone H3 strongly and H4 weakly in a free histone mixture (although histone H4 
was well acetylated individually). Protein sequence analysis of these reaction 
products revealed that the primary sites of acetylation were lysine 14 on histone H3 
and lysines 8 and 16 on histone H4 (Kuo et al., 1996). Although recombinant 
yGCN5 proved able to acetylate free histones efficiently, it was unable to acetylate 
nucleosomal histones (Grant et al., 1997; Kuo et al., 1996; Ruiz-Garcia et al., 
1997), the more physiological substrates, except under special conditions and at 
high enzyme concentrations (Tse et al., 1998). The lack of nucleosomal HAT 
activity suggested that other factors are required to regulate either the recognition 
of histone substrates within the nucleosome or the catalytic activity of the enzyme 
in this altered context. 
Early studies involving yGCN5 demonstrated its ability to functionally interact both 
in vitro and in vivo with two adaptor proteins, Ada2 and Ada3, to form a trimeric 
complex with the ability to promote transcriptional activation (Marcus et al., 1994) 
(Candau et al., 1996; Horiuchi et al., 1995). While it was subsequently shown that 
the heterotrimeric complex formed by GCN5, Ada2, and Ada3 has indeed the 
ability to acetylate nucleosomal histones (Balasubramanian et al., 2002), its native 
association with other proteins to form larger chromatin-modifying complexes had 
not yet been explored. The search for these complexes possessing HAT activity 
resulted in the identification of four distinct complexes with the ability to acetylate 
nucleosomal histones in yeast (Grant et al., 1997). Two of these four complexes 
were shown to contain GCN5 and the adaptor protein Ada2, suggesting that they 
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possessed the necessary catalytic activity and targeting ability to function as 
multisubunit HAT complexes. Subsequent characterization of the highest molecular 
weight HAT complex, estimated at 1.8 MDa, identified several additional subunits, 
including members of the suppressor of Ty (Spt) protein family, Spt3, Spt7 and 
Spt20. The discovery of these subunits in association with the high molecular 
weight HAT complex led its naming as the Spt-Ada-GCN5 acetyltransferase 
(SAGA) complex. During initial characterization of the yeast SAGA complex it was 
shown that deletion of GCN5, Ada2, or Ada3 resulted in loss of HAT activity, 
indicating that Gcn5 was the sole HAT responsible for SAGA-mediated histone 
acetylation. Additionally, these experiments demonstrated that the adaptor proteins 
Ada2 and Ada3 were required for mediating the activity of Gcn5 in a physiologically 
relevant context. While GCN5, Ada2, and Ada3 were not required for the overall 
integrity of the complex, they were shown to be critical for its ability to recognize 
and acetylate nucleosomal substrates and defined the GCN5-Ada2-Ada3 
heterotrimer as the catalytic core of the SAGA complex (Grant et al., 1997). It was 
later determined that there was a second GCN5-containing protein complex in 
yeast that functioned in stress-response pathways and shared a similar subunit 
composition and histone substrate specificity with SAGA (Pray-Grant et al., 2002; 
Sterner et al., 2002). Due to its similarity to SAGA, this second GCN5-containing 
complex was named the SAGA-like (SLIK) complex. Both the SAGA and SLIK 
complexes represent examples of how histone acetylation by GCN5 is controlled 
through its interactions with accessory factors in the context of multiprotein 
chromatin-modifying complexes. The composition and functions of these yeast 
HAT complexes has served as the as the basis for the identification and 




Figure 9. The overall structure of the GCN5 and PCAF enzymes in vertebrates, Drosophila and 
yeast. Schematic representation and domain organization of the GCN5 and PCAF proteins from human 
(hs; Homo sapiens), chicken (gg; Gallus gallus), zebrafish (dr; Danio rerio), pufferfish (tn; Tetraodon 
nigroviridis), Drosophila melanogaster (dm) and yeast (sc; Saccharomyces cerevisiae) are shown. The 
PCAF homology domain (PCAF-HD) is shown in grey, the acetyltransferase (AT) domain is shown in 
black and the bromodomain (Bromo) is shaded. The numbers over the boxes indicate amino acid 
positions. The identity between the different factors is indicated in % on the right of the horizontal lines, 
representing the pair wise comparisons. (Nagy and Tora, 2007). 
Unlike yeast, metazoans possess two GCN5 isoforms that are believed to arise 
from the alternative splicing of a single gene product (Smith et al., 1998). The lower 
molecular weight isoform (GCN5-S) contains both a HAT domain and a single 
bromodomain and is similar in size and function to the single form of Gcn5 found in 
yeast. The second, higher molecular weight isoform (GCN5-L) has been shown to 
contain an additional N-terminal domain that presents high similarity to the N-
terminal domain of the GCN5 homolog PCAF (Xu et al., 1998) (Figure 9).  
The function of human GCN5 (also known as hGCN5) has been investigated in 
vitro and in vivo, and it was found to carry out transcriptional coactivator roles 
analogous to those of yGCN5 (Candau et al., 1996). Further studies revealed that 
hGCN5 possesses HAT activity in vitro (Yang et al., 1996b), and its HAT domain 
can successfully substitute for that of yGCN5 in vivo, indicating the evolutionary 
conservation of this HAT function (Wang et al., 1997). However, in contrast to 
yGCN5, the larger GCN5 isoform found in higher eukaryotes is able to acetylate 
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histones H3 and H4 in both the free and nucleosome-incorporated states in vitro, 
without the presence of accessory proteins (Xu et al., 1998). The ability of free 
GCN5-L protein to acetylate nucleosomal histones in more complex organisms is 
presumably dependent on the presence of the additional N-terminal domain, which 
is absent from yeast GCN5.  
GCN5 isoforms serve as the catalytic HAT subunits in several multiprotein 
complexes in human cells, including the STAGA, TFTC and ATAC complexes, 
which will be the argument of the following section. Interestingly, the vertebrate-
specific HAT PCAF, identified as a paralog of human GCN5 (Yang et al., 1996b), 
can also function as the catalytic subunit of these HAT complexes. 
Metazoan GCN5-containing complexes 
Analyses of protein samples purified from either Drosophila or human cell nuclear 
extracts separated by size suggested that, in metazoans, GCN5 is the catalytic 
subunit of at least two types of multiprotein complexes, one having a molecular 
weight of 2 MDa, and a second type with a size of about 700 kDA. The 2 MDa 
GCN5-containing complexes in metazoans are the STAGA (SPT3-TAF9-GCN5 
acetyltransferase) and the TFTC (TBP-free-TAF) complexes (Brand et al., 1999; 
Martinez et al., 1998; Wieczorek et al., 1998). In addition to GCN5, all of them 
contain a set of Tata binding protein (TBP)-associated factors (TAFs) and several 
human homologs of proteins that were earlier identified in yeast as necessary for 
either correct transcription initiation site selection by RNA Pol II (the Spt group of 
proteins (Winston and Sudarsanam, 1998)) or transcriptional activation (the Ada 
group of adaptor proteins (Berger et al., 1992; Pina et al., 1993; Roberts and 
Winston, 1996)). The human 2 MDa complexes also contain a 400 kDa protein, 
TRRAP (transactivation/transformation domain associated protein), which was 
originally isolated as a Myc-associated transcriptional coactivator (McMahon et al., 
1998). Since their original identification, a lot of information has been published on 
the subunit composition and function of the STAGA and TFTC complexes (Brand 
et al., 2001; Cavusoglu et al., 2003; Demeny et al., 2007; Helmlinger et al., 2004; 
Martinez et al., 2001; Palhan et al., 2005). As a result, today these 2MDa GCN5-
containing complexes appear to be very similar and highly homologous to the 
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yeast SAGA complex. Genetic and biochemical analysis in Drosophila led to the 
conclusion that the 2MDa GCN5-containing complexes play multiple roles in the 
cells. The first would be the deposition of histone H3 acetylation marks along the 
entire chromosomes, while the second would be the targeted acetylation of 
histones at specific loci. Evidence exists that the equivalent vertebrate complexes 
also play a role in global chromosome acetylation, since total histone preparations 
from GCN5-lacking cells show very drastic changes in several differently deposited 
acetyl marks (Kikuchi et al., 2005). If such changes occurred only at certain specific 
gene loci, they would not be detectable in total histone preparations. Conversely, 
increased levels of GCN5 alone can strongly augment global nuclear acetylation, 
indicating that GCN5 has widespread global effects on the chromatin acetylation 
state, independent of its recruitment by activators (Knoepfler et al., 2006). Another 
study also described the role of STAGA/TFTC in global chromatin decondensation 
(Helmlinger et al., 2006). SCA7 (spinocerebellar ataxia 7) is one of the several 
neurodegenerative disorders caused by a polyglutamine (polyQ) expansion, but it 
is the only one in which the retina is affected. Vertebrate Ataxin-7, homologue of 
yeast Sca7 SAGA component, is a subunit of the STAGA/TFTC-type complexes 
(Helmlinger et al., 2004; Palhan et al., 2005). Studying the effect of polyQ-
expanded Ataxin-7 on STAGA/TFTC activity revealed an interesting connection 
between the function of these complexes and global histone acetylation. Careful 
examination of mouse photoreceptors, in which polyQ-expanded Ataxin-7 had 
been exogenously expressed, indicated a dramatic increase in the photoreceptor 
nuclear volume, probably due to chromatin decondensation (Helmlinger et al., 
2006). Histone hyperacetylation caused by the aberrant HAT function of the polyQ-
containing STAGA/TFTC complexes has been hypothesized to account for the 
global chromatin decondensation (Helmlinger et al., 2006). Thus, it seems that 
hyperacetylation and the consequent dramatic chromatin decondensation disrupts 
the normally highly compacted chromatin architecture of the differentiated 
photoreceptor nuclei. 
Many metazoan transcriptional activators and cell cycle regulatory proteins directly 
contact and recruit GCN5-containing complexes to specific promoters (Anafi et al., 
2000; Flinn et al., 2002; Kahata et al., 2004; Lebedeva et al., 2005; Liu et al., 2003; 
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McMahon et al., 1998; Paulson et al., 2002; Yanagisawa et al., 2002). According to 
the most accepted model (Carrozza et al., 2003), these activators would directly 
contact the TRRAP subunit of the STAGA/TFTC complexes; however, preceding 
histone modifications created by other chromatin-modifying complexes may also 
influence the recruitment. Once targeted, STAGA/TFTC complexes mainly 
acetylate histone H3 in the proximity of promoters and, in such a way, they are 
thought to stabilize their own binding to these promoter regions. In addition, it 
appears that the targeted binding of ATP-dependent chromatin-remodeling 
complexes, containing subunits with bromodomains, also requires GCN5-
dependent acetylation (Carrozza et al., 2003; Hassan et al., 2001). 
Similarly to the yeast SAGA, STAGA/TFTC complexes also contain a subunit 
functioning as H2B ubiquitin protease, USP22 in humans (corresponding to the 
Ubp8 SAGA component), which can specifically remove the monoubiquitin moiety 
from histone H2B (Daniel et al., 2004; Henry et al., 2003; Weake et al., 2008; Zhao 
et al., 2008). Given the regulatory effect that monoubiquitinated histone H2B exerts 
on transcriptional initiation and subsequent elongation of the nascent transcript by 
RNA pol II in yeast (Wyce et al., 2007), it appears that the SAGA complex and its 
counterparts found in higher eucaryotes can facilitate transcriptional activation and 
elongation not only through acetylation of chromatin, but also through the 
modulation of histone ubiquitination.  
The STAGA/TFTC-type complexes are also believed to play a role in linking 
chromatin modifications and DNA repair mechanisms. Since STAGA/TFTC was 
shown to possess higher binding affinity to UV-irradiated DNA and enhanced 
acetylation activity on nucleosomes formed on irradiated DNA (Brand et al., 2001), 
the possibility was raised that these complexes may be involved in making the 
DNA damage more accessible to the repair machinery in the context of chromatin. 
According to the proposed model, STAGA/TFTC, by binding to UV lesions, would 
deliver HAT activity to the damaged sites, consequently loosening up the 
chromatin structure around these regions and thus facilitating the rapid access of 
the DNA repair machinery to the UV lesions. This is consistent with the observation 
that DNA repair synthesis is enhanced on hyperacetylated nucleosomes, and that 
nucleotide excision repair (NER) is facilitated by ATP-dependent chromatin-
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remodeling factors, which may be recruited after or during the acetylation signal 
has been deposited by GCN5 (Ura et al., 2001). 
Finally, metazoan 2 MDa GCN5-containing complexes are known to function as 
cofactors for several oncoproteins. For instance, in human cells, following mitogen-
mediated activation, the Myc oncoprotein recruits STAGA/TFTC-type complexes as 
transcriptional coactivators to Myc-dependent promoters through the interaction 
with their TRRAP subunit (Frank et al., 2001). Consistently, a naturally occurring 
truncated form of Myc, which does not interact with purified STAGA complex, 
shows reduced transcription activation potential and cannot transform primary cells 
(Spotts et al., 1997). In addition, Myc-dependent transcription and cell proliferation 
requires the integrity of the STAGA complex (Liu et al., 2008). These results 
suggest that Myc activates transcription of target genes via mechanisms that 
involve modification of the chromatin structure partly through TRRAP-mediated 
recruitment of GCN5-containing HAT complexes. Therefore, the oncogenic 
transformation carried out by Myc is not a result of the protein per se, but rather 
depends on its physical and functional contact with multisubunit GCN5-containing 
complexes. 
In the past few years, an additional GCN5-containing complex has been described 
from metazoans, called ATAC (ADA-two-a-containing) (Guelman et al., 2009; 
Guelman et al., 2006; Suganuma et al., 2008; Wang et al., 2008). The first 
indication of its existence came from the discovery that the yeast Ada2 protein has 
two orthologues in metazoans: ADA2a and ADA2b (Kusch et al., 2003; Muratoglu 
et al., 2003). In fly embryo extracts, ADA2a co-fractionates with GCN5 in the 600-
700 kDa size range, while ADA2b copurifies with the 2 MDa STAGA-type 
complexes (Kusch et al., 2003; Muratoglu et al., 2003). After this finding, the affinity 
purification of the Drosophila 700 kDa ATAC complex (dATAC) was reported 
(Guelman et al., 2006). dATAC has been shown to possess different substrate 
specificity than dSTAGA, as it mainly acetylates histone H4 (Ciurciu et al., 2006; 
Guelman et al., 2006; Suganuma et al., 2008). Interestingly, further 
characterization of dATAC established that a second HAT enzyme, dATAC2, is 
also part of the complex and seems to be responsible for the H4-specific 
acetylation activity (Suganuma et al., 2008). The differential histone acetylation 
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patterns induced by the activity of the two complexes seem to determine distinct 
functions in changing the chromatin structure and also in consequent downstream 
regulatory events. Given the high conservation of the known subunits of both 
dSTAGA and dATAC through evolution (Lee and Workman, 2007; Nagy and Tora, 
2007), the identification of an ATAC-like complex in vertebrates was expected. 
Indeed, purification and characterization of the endogenous human ATAC complex 
(hATAC) were recently reported (Nagy et al., 2010), thus validating previous results 
obtained by overexpressing one of the ATAC subunits and using it for subsequent 
immunopurification (Guelman et al., 2009; Wang et al., 2008). The hATAC complex 
shares a common core with STAGA, composed of GCN5-ADA3-SGF29 and either 
ADA2a (in ATAC) or ADA2b (in SAGA). Besides these subunits, hATAC contains a 
second putative HAT, called hATAC2, as well as several other subunits involved in 
transcriptional regulation (hNC2β), nucleosome remodelling (hWDR5), cell growth 
(hYEATS2) and potential DNA binding (hZZZ3) (Guelman et al., 2009; Nagy et al., 
2010; Wang et al., 2008). However, since the analysis of endogenous or Flag-
purified hATAC highlighted a surprisingly large and variable size of this complex 
(from 2 MDa to about 600 kDa) (Guelman et al., 2009), while the sum of the 
masses of the already identified components is only about 800 kDa, the future 
identification of new subunits is expected. With regard to the substrate specificity of 
hATAC, differently from what observed in Drosophila, in humans both the STAGA 
and ATAC complexes exhibit the same specificity towards histones H3 and H4 
(Guelman et al., 2009; Nagy et al., 2010; Wang et al., 2008). What is then the 
biological relevance of having two GCN5-containing HAT complexes, STAGA and 
ATAC, in humans? A potential explanation came from a recent study, where the 
genome-wide binding map of the two GCN5-containing HAT complexes, STAGA 
and ATAC, was determined in two human cell lines (Krebs et al., 2011). The results 
of this study showed that the recruitment of the two complexes is highly specific, as 
their binding sites show little overlap and they bind to distinct functional elements. 
Infact, ATAC is recruited to enhancers and promoters, while STAGA is mainly 
recruited to promoters. STAGA and ATAC bound genes are mostly active, yet they 
represent only a subset of active genes, suggesting that they function as 
coactivators for specific expression programs. Interestingly, the same study also 
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defined an as-yet-undescribed role for ATAC in the regulation of a limited set of 
enhancers, which differ from all previously known ones, since they are not bound 
by p300 (Krebs et al., 2011). Finally, another novel and specific function of ATAC 
has been recently identified in controlling the activity of the Cyclin A/Cdk2 complex, 
and consequently the cell cycle progression, through direct acetylation of Cyclin A, 
which in turn targets the protein for degradation (Orpinell et al., 2010). 
GCN5 and PCAF exhibit distinct, yet partially overlapping functions 
While most of the metazoan genomes code for one GCN5-type factor, vertebrates 
have a second gene encoding PCAF, which is highly homologous to GCN5 (Nagy 
and Tora, 2007; Sterner and Berger, 2000; Yang, 2004b) (Figure 9). Available data 
(Gamper and Roeder, 2008; Nagy et al.) suggest that both GCN5 and PCAF form 
STAGA- and ATAC-type complexes. The presence of GCN5 or PCAF in these 
complexes appears to be mutually exclusive, and even all the four possibilities may 
coexist in one cell (meaning that GCN5-containing STAGA and ATAC complexes 
can be present together with PCAF-containing STAGA and ATAC complexes). 
To better understand the physiological roles of GCN5 and PCAF, knockout mice 
were generated harboring deletions of the GCN5 locus, the PCAF locus, or both, 
and the effects of such deletions on the development and adult phenotype of the 
transgenic models were examined. Despite the high similarity between the two 
proteins, their control over embryogenesis was shown to be quite disparate. 
Surprisingly, homozygous deletion of the PCAF gene resulted in a lack of physical 
impairment in adult mice (Yamauchi et al., 2000). Loss of PCAF expression, 
however, led to neurological dysfunction in young adult mice, including memory 
deficit and an exaggerated response to externally applied stress (Maurice et al., 
2008). In contrast, despite a lack of phenotype in heterozygous GCN5 knockout 
mice, loss of both GCN5 alleles led to embryonic lethality that was associated with 
an increase in apoptosis and a failure to complete neural tube development (Xu et 
al., 2000; Yamauchi et al., 2000). Homozygous deletion of both PCAF and GCN5 
alleles led to embryonic lethality occurring at earlier stages in development than 
that observed in GCN5-null mice, thus suggesting that the two proteins are 
required for functionally distinct processes. Not surprisingly, considering the distinct 
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phenotypes of GCN5- and PCAF-null mice, GCN5 mRNA was found to be highly 
expressed until later stages during embryonic development, while PCAF mRNA 
was barely detectable until mice reached adulthood (Xu et al., 2000). Additional 
analysis of tissues from these mouse models indicated that expression of GCN5 
increased in response to loss of PCAF (Yamauchi et al., 2000). Coupled with the 
more severe developmental phenotype observed in mice lacking both PCAF and 
GCN5, these findings indicated that these two HATs exhibit partially overlapping, 
yet distinct functions. 
The idea that GCN5 and PCAF have partially overlapping functions has been 
further supported by experiments performed in cultured chicken cells, which 
demonstrated a robust upregulation of PCAF expression in response to loss of 
GCN5 (Kikuchi et al., 2005). The observed compensation for loss of GCN5 was 
PCAF-specific, since the expression of other HATs was not significantly altered. 
Similarly, in nuclear extracts prepared from MEFs derived from GCN5 knockout 
mice, PCAF expression was significantly up-regulated (2- to 3-fold), suggesting 
that, when GCN5 is inactivated, cells try to compensate the loss of its activity with 
that of its paralogue (Nagy et al., 2010). However, altered patterns of histone H3 
and H4 acetylation were observed in GCN5-lacking cells and gene expression 
analyses revealed that the GCN5-deficiency specifically affected the transcription 
of G1/S checkpoint-related genes and also that of some apoptosis-related ones 
(Kikuchi et al., 2005), thus indicating that the functions of GCN5 and PCAF are 
partially overlapping, yet not redundant in a given cell, and that GCN5 has unique 
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Plasmids 
Construction of pGEX-IN has previously been described (Cereseto et al., 2005). 
pcDNA3-HA-IN was obtained by subcloning IN sequence from pGEX-IN plasmid 
into pcDNA3-HA vector. pGEX-IN and pcDNA3-HA-IN fragments were produced by 
PCR amplification of IN with primers specific to the deleted forms. pASK-IBA37-IN 
was constructed by subcloning IN sequence from pGEX-IN plasmid into pASK-
IBA37 vector (IBA GmbH, Göttingen, DE). pFlag-IN codon optimized (c.o.) was 
kindly provided by A. Engelman. pASK-IBA37-IN point mutants and pFlag-IN c.o. 
K264,266,273R and K258,264,266,273R were obtained by PCR-based site-
directed mutagenesis starting from the corresponding plasmids encoding wild type 
IN. 
pGEX-GCN5 was a kind gift of M. Benkirane. pcDNA3-HA-GCN5 was constructed 
by subcloning GCN5 sequence from pGEX-GCN5 plasmid into pcDNA3-HA vector. 
pcDNA3-HA-GCN5 (Y260A/F261A) (Paulson et al., 2002) was obtained by PCR-
based site-directed mutagenesis starting from the plasmid encoding wild type 
GCN5. 
For production of IN-GCN5 tethered catalysis constructs, the sequence coding for 
the 6-300 amino acid region of GCN5 was amplified by PCR from pcDNA3-HA-
GCN5 or pcDNA3-HA-GCN5 (Y260A/F261A) and cloned into pASK-IBA37 vector 
downstream and in frame with c.o. IN. The sequence encoding TEV protease 
recognition site was inserted by PCR between IN and GCN5 cDNAs. 
pGIPZ and pGIPZGCN5 lentiviral vectors were purchased from Open Biosystems 
(Huntsville, AL). The sequence of GCN5 shRNAmir inserted into the pGIPZGCN5 
vector is as follows: 5′-CCCATTCATTCCCTGGCATTAATAGTGAAGCCACAG 
ATGTATTAATGCCAGGGAATGAATGGT-3′. For production of pGIPZGCN5 mut 
vector, four point mutations were introduced in the shRNAmir cassette of 
pGIPZGCN5, obtaining the following sequence: 5′-CCCATTCAAAGGCTGGCA 
TTAATAGTGAAGCCACAGATGTATTAATGCCAGCCTTTGAATGGT-3′, where 
mutated nucleotides are underlined. 
The NL4.3-Luc env-deleted virus expressing the luciferase reporter gene was 
produced from the pNL4.3.Luc.R-E- molecular clone obtained from the AIDS 
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Research and Reference Reagent Program, Division of AIDS, NIAID, NIH. For 
construction of pNL4.3.Luc.R-E-/IN WT and pNL4.3/IN WT plasmids, IN sequence 
was subcloned from the molecular clone pHXB2. The IN mutations in 
pNL4.3.Luc.R-E-/IN K264,266,273R, pNL4.3.Luc.R-E-/IN K258,264,266,273R, 
pNL4.3/IN K264,266,273R and pNL4.3/IN K258,264,266,273R were introduced by 
PCR-based site-directed mutagenesis using the corresponding viral clones 
encoding wild type IN as templates. 
The envelope plasmid pMDG and the packaging plasmid pCMVΔR8.91 were kindly 
provided by Z. Debyser. 
Recombinant proteins production and proteolytic 
processing 
GST fusion proteins were purified from Escherichia Coli BL21 cells transformed 
with the respective plasmids. Bacterial cultures were grown at 37 °C in terrific broth 
supplemented with 100 mg/ml ampicillin until reaching an absorbance of 0.6 OD600. 
Protein expression was induced with 1 mM IPTG and the incubation was continued 
for 3 h at 30 °C. Bacterial cells were pelleted, resuspended in cold lysis buffer (1× 
PBS pH 7.4, 50mM EDTA pH 8.0, 1% Triton X-100, 2 mM DTT, 1 mM PMSF), and 
sonicated by 4 pulses of 15 s each. Cleared lysates were mixed with a 50% slurry 
of glutathione Sepharose beads, and GST fusion proteins were allowed to bind to 
the resin at 4 °C on a rotating wheel. After 2 h of incubation, the beads were spun 
down by centrifugation and washed for three times with 10 bed volumes of lysis 
buffer. For the elution of GST fusion proteins, 1 bed volume of elution buffer (50 
mM Tris-HCl pH 8.0, 25 mM reduced glutathione) was added to the resin. After 
incubation of the mixture at 4 °C on a rotating wheel for 15 min, the beads were 
spun down by centrifugation and the supernant (containing the eluted GST fusion 
proteins) was collected. The elution procedure was repeated for three times. Eluted 
proteins were dyalised overnight at 4 °C against one liter of dyalisis buffer (20 mM 
Tris-HCl, pH 8.0, 100 mM KCl, 20% glycerol). 
N-terminal 6×His-tagged IN proteins were expressed in Escherichia Coli BL21 
strain and purified by metal ion affinity chromatography (BD TALON Metal Affinity 
Resin, BD Biosciences, Palo Alto, CA) according to a previously reported protocol 
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(Bushman et al., 1993), with minor modifications. Briefly, bacterial pellets were 
resuspended in cold lysis buffer (20 mM Tris-HCl, pH 8.0, 1 M NaCl, 0.5% Triton X-
100, 1 mM PMSF, 5mM imidazole) and sonicated by 4 pulses of 15 s each. 
Cleared lysates were incubated with a 50% BD TALON Resin slurry at 4 °C on a 
rotating wheel for 2 h. The lysate/BD Talon Resin suspension was loaded into an 
empty plastic column (Bio-Rad, Richmond, CA), letting the unbound proteins to 
pass through, and the resin was washed for three times with 10 bed volumes of 
wash buffer (20 mM Tris-HCl, pH 8.0, 1 M NaCl, 0.5% Triton X-100, 10 mM 
imidazole). 6×His-tagged proteins were eluted with 1 bed volume of elution buffer 
(20 mM Tris-HCl, pH 8.0, 1 M NaCl, 0.1% Triton X-100, 200 mM imidazole), 
repeating the procedure for four times. Eluted proteins were dyalised against one 
liter of dialysis buffer (20 mM Tris-HCl, pH 8.0, 1 M NaCl, 10% glycerol, 1 mM DTT) 
overnight at 4 °C. 
Proteolytic processing of IN-GCN5 chimeras was performed by incubating 20 µg of 
fusion protein with 30 U of TEV protease (AcTEV Protease, Invitrogen, Inc., 
Carlsbad, CA) in a buffer containing 50 mM Tris-HCl, pH 8.0, 0.5 mM EDTA, 0.1 M 
NaCl, 1 mM DTT and 10% glycerol, overnight at 4°C. 6×His-tagged IN was then 
recovered from the reaction mixture by adsorption on BD TALON Resin. The purity 
and integrity of purified proteins were checked by SDS-PAGE followed by 
Coomassie Blue staining. 
In vitro acetylation assay 
In vitro acetylation assays were performed as previously reported with minor 
modifications (Cereseto et al., 2005). Briefly, GST or 6×His-tag fusion proteins 
were incubated with GST-GCN5 and [14C]-acetyl-CoA in HAT buffer (50 mM Tris-
HCl, pH 8.0, 5% glycerol, 0.1 M EDTA, 50 mM KCl, 2 mM sodium butyrate) in a 
final volume of 30 µl for 45 min at 30°C. Following SDS-PAGE resolution of the 
reaction mixtures, acetylated proteins were visualized by phosphoimaging 
(Cyclone). 
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In vitro binding assay 
[35S]-labeled IN proteins used for in vitro binding assays were produced from the 
corresponding pcDNA3-HA plasmids by using the TNT Reticulocyte Lysate System 
(Promega Corp., Madison, WI). Analysis of in vitro binding between GST fusion 
proteins and [35S]-IN or [35S]-IN fragments was performed as previously described 
(Cereseto et al., 2005). Briefly, GST fusion proteins (1 µg) immobilized on 
glutathione Sepharose beads, after pre-treatment in a solution containing DNase I 
0.25 U/µl and RNase H 0.25 U/µl, were incubated for 1 h at 4 °C with 600 c.p.m. of 
in vitro translated [35S]-proteins in NETN buffer (20 mM Tris-HCl, pH 7.5, 100 mM 
NaCl, 1mM EDTA, 0.5% NP-40, 1mM DTT, 1mM PMSF) supplemented with 0.2 
mg/ml ethidium bromide. Following extensive washes, the reaction mixtures were 
resolved by SDS-PAGE and radiolabeled proteins visualized by phosphoimaging 
(Cyclone). 
In vitro integration assays 
Oligonucleotide substrates for in vitro integration assays were as follows: 70 (5′-
GTGTGGAAAATCTCTAGCAGT-3′), 71 (5′-GTGTGGAAAATCTCTAGCA-3′), and 
72 (5′-ACTGCTAGAGATTTTCCACAC-3′) (Parissi et al., 2001). 70 or 71 
oligonucleotides were labeled with 32P using polynucleotide kinase and annealed to 
the complementary 72 oligonucleotide. 3′ end processing reaction was performed 
in a buffer containing 25 mM MOPS, 5% PEG-8000, 5% DMSO, 0.05% NP-40, 30 
mM NaCl and 10 mM DTT, in the presence of the 70/72 blunt substrate. Strand 
transfer reaction was carried out in 20 mM Hepes, pH 7.2, 7.5 mM MnCl2, 0.05% 
NP-40 and 10 mM DTT, in the presence of the 71/72 substrate. For both assays, 
[32P]-labeled duplex DNAs (1 pmol) were incubated in a final volume of 20 µl with 
100 or 200 ng of recombinant IN derived from GCN5 wild type or mutant fusion 
protein at 37 °C for 1 h. The reaction products were resolved by electrophoresis on 
a 15% polyacrylamide gel with 7M urea in Tris-Borate-EDTA buffer, pH 7.6, and 
then visualized by phosphoimaging (Cyclone). 
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Cell culture and transfection 
HeLa and HEK 293T cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin and 
100 µg/ml streptomycin. HEK 293T cells stably transduced with pGIPZ lentiviral 
vectors were grown with the addition of puromycin 2 µg/ml. CEM T cells were 
cultured in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented 
with 10% FCS, 2 mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. 
Transfections were performed by the standard calcium phosphate coprecipitation 
procedure, or by using the polyethylenimine (PEI) reagent (MW 25000, Sigma, Inc., 
St Louis, MO) according to a previously reported protocol (Durocher et al., 2002). 
Immunoprecipitation and Western blotting 
For immunoprecipitation, cell pellets were lysed 36 h after transfection in RIPA 
buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% 
deoxycolic acid) containing 10 mM sodium butyrate (Sigma, Inc.) and protease 
inhibitors (Complete Protease Inhibitor Cocktail Tablets, Roche Diagnostics, 
Indianapolis, IN). The protein concentration of cell extracts was determined by 
Bradford assay (Bio-Rad). Anti-Flag M2 affinity resin or rat monoclonal anti-HA 
antibody were incubated overnight at 4 °C with the cell lysates (2 mg of total 
proteins for coimmunoprecipitation or 4 mg for in vivo acetylation experiments). 
The HA-immune complexes were precipitated by incubation with UltraLink 
Immobilized Protein G (Pierce Biotechnology, Inc., Rockford, IL). The precipitated 
complexes were then extensively washed and analyzed by Western blotting using 
the appropriate antibodies. 
Antibodies 
The following primary antibodies were used: rabbit anti-acetylated-lysine (Cell 
Signaling Technology, Inc., Danvers, MA); mouse anti-Flag M2 (Sigma, Inc.), either 
free or bound to agarose beads; rat anti-HA Clone 3F10 (Roche Diagnostics); 
mouse anti-IN 8G4, obtained from the AIDS Research and Reference Reagent 
Program; rabbit anti-GCN5 H-75 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA); 
and mouse anti-α-tubulin Clone B-5-1-2 (Sigma, Inc.). 
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For the production of a polyclonal, anti-acetylated IN antibody, three rabbits were 
immunized with a peptide corresponding to amino acids 261-280 of the IN 
sequence, chemically acetylated at lysines 264, 266 and 273, after conjugation 
with Maleimide Activated mcKLH (Pierce Biotechnology, Inc.). The IgG fraction was 
obtained from collected sera with the use of ImmunoPure (A) IgG Purification Kit 
(Pierce Biotechnology, Inc.). The purified samples were then passed over a column 
conjugated with the unmodified IN peptide to remove the antibody cross-reacting 
with non-acetylated IN. 
Secondary horseradish peroxidase (HRP)-conjugated antibodies against mouse or 
rabbit Igs were purchased by Santa Cruz Biotechnology, Inc. For detection of IN 
acetylation with anti-acetylated-lysine antibody, Biotin-SP-conjugated AffiniPure 
F(ab′)2 Fragment Donkey Anti-Rabbit IgG (H+L) (Jackson ImmunoResearch 
Laboratories, Inc., West Grove, PA) and ECL Streptavidin-HRP conjugate 
(Amersham Biosciences Corp., Piscataway, NJ) were employed. 
Virus and viral vector production 
For production of env deleted, VSV-G pseudotyped NL4.3-Luc viral stocks, 6×106 
HEK 293T cells were seeded in 100 mm dishes in Optimem (Invitrogen, Inc.) 
containing 2% FCS. After 24 h of incubation, the medium was replaced by 
Optimem without FCS and cells were transfected with 20 µg of pNL4.3.Luc.R-E- 
(either wild type or mutated) and 5 µg of the envelope plasmid pMDG using the PEI 
reagent (Sigma, Inc.). The cell culture supernatant was collected 48 h after 
transfection and filtered through a 0.45 µM pore size filter. 
NL4.3 replication competent viruses were prepared as described for NL4.3-Luc 
viral clones, using 25 µg of pNL4.3 plasmid (wild type or mutated) for transfections. 
For the generation of viral vector stocks, HEK 293T cells were transfected with 10 
µg of the packaging plasmid pCMVΔR8.91, 5 µg of pMDG, and 20 µg of the gene 
transfer plasmid (pGIPZ, pGIPZGCN5, or pGIPZGCN5 mut) following the protocol 
used for virus production. The cell culture supernatant was collected twice, at 48 
and 72 h after transfection, filtered through a 0.45 µM pore size filter and 
concentrated by ultracentrifugation at 110000 × g for 2 h at 4 °C. 
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Both viruses and viral vectors were titered by quantification of p24 antigen in cell 
culture supernatants with an enzyme-linked immunoabsorbent assay 
(Innogenetics, Gent, Belgium). 
Transient and stable knockdown of GCN5 expression 
GCN5-targeting siRNA (Dharmacon Research, Boulder, CO) had the following 
plus-strand sequence: 5′-AACCAUGGAGCUGGUCAAUGAAA-3′. As a non-
silencing control, Dharmacon ON-TARGETplus siCONTROL Non-Targeting Pool 
was employed. 
HeLa cells, seeded in 6-well plates the day before treatment (1.5×106 cells/well), 
were transfected twice at a 24 h interval with 150 nM siRNA using Gene Silencer 
reagent as recommended by the manufacturer (Gene Therapy Systems, Inc., San 
Diego, CA). Cells trypsinized after 20 h were either plated for infections, or lysed 
for Western blot analysis. 
For production of stably silenced cell lines, HEK 293T cells, seeded in 24-well 
plates the day before transduction (5×104 cells/well), were incubated for 4 h with 1 
µg p24 antigen of the appropriate pGIPZ lentiviral vector (encoding GCN5 
shRNAmir, GCN5 shRNAmir mut or lacking a silencing insert). Two days after 
transduction, selection with 2 µg/ml puromycin was initiated. For selection of GCN5 
knockdown cell clones, the clones with the highest GFP expression levels, as 
determined by fluorescence-activated cell sorting analysis (FACS), were chosen. 
HIV-1 infectivity assays 
For single-round viral replication assays, siRNA-treated HeLa cells (2.5×106/well) 
or HEK 293T cells (5×106/well) were seeded in 6-well plates and incubated for 3 h, 
in a total volume of 500 µl, with 50 or 100 ng p24 antigen of NL4.3-Luc virus (wild 
type or mutated), respectively. Cells were collected 48 h after infection and lysed 
for measurement of luciferase activity (Luciferase Assay System, Promega Corp.). 
Luminometer readouts, expressed as relative light units (RLU), were normalized 
with respect to protein concentration in each sample. 
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Viral stocks used in infections for measurement of HIV-1 DNA species by real time 
quantitative PCR (RT-Q-PCR) were pre-treated for 1 h at 37 °C with 160 U/ml 
Turbo DNase (Ambion, Inc., Austin, TX). 
For multiple-round infections, 1×106 CEM T cells were incubated with 1 or 10 ng 
p24 antigen of NL4.3 virus (wild-type or mutated), in a total volume of 500 µl. After 
3 h, cells were washed twice with PBS containing 1% FCS and put in culture in a 6-
well plate at a density of 0.5×106 cells/ml. After 3 days, cells were counted, spun 
down by centrifugation and supernatant was collected. Cells were then 
resuspended in fresh medium and put in culture again at a density of 0.5×106 
cells/ml. This procedure was repeated every 3 days over a period of 21 days. Viral 
titers in the collected supernatants were determined by a 32P-based RT assay 
performed by standard procedures. 
RT-Q-PCR analysis 
Total DNA was extracted from HEK 293T cells with the DNeasy Tissue Kit 
(QIAGEN GmbH, Hilden, DE) at different time points after infection. Amplification 
reactions were performed with the Light Cycler 480 instrument (Roche 
Diagnostics). Quantification of total HIV-1 DNA was performed at 24 h post 
infection with a pair of primers (LucFw, LucRev) and a fluorogenic hybridization 
probe (LucProbe) annealing to the luciferase reporter gene of NL4.3-Luc viral clone 
(Table 1). Reaction mixtures contained 500 ng of total cellular DNA, 1× Light Cycler 
480 Probe Master (Roche Diagnostics), 300 nM each forward and reverse primers 
and 200 nM probe in a total volume of 20 µl. After an initial denaturation step (95 
°C for 10 min), the cycling profile was 40 cycles consisting of 95 °C for 30 s, 60 °C 
for 30 s, and 72 °C for 30 s. This protocol was also used for detection of integrated 
HIV-1 DNA at 14 days after infection in HEK 293T cells stably transduced with 
pGIPZ lentiviral vectors. 
Quantification of proviral DNA at 48 h post infection in HEK 293T cells was 
performed by Alu-LTR nested PCR. In the first amplication step, two outward-
facing primers annealing within the highly repeated chromosomal Alu element (Alu 
1 and Alu 2) were used together with a HIV-1 LTR-specific primer containing a 
lambda phage-specific heel sequence at its 5′ end (L-M667) (Table 1). Alu-LTR 
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sequences were amplified from 500 ng of total cellular DNA in a 20 µl reaction 
mixture comprising 1× Light Cycler 480 Probe Master (Roche Diagnostics), 100 nM 
L-M667 primer, and 300 nM (each) primers Alu 1 and Alu 2. The first-round PCR 
cycle conditions were as follows: a denaturation step of 8 min at 95°C followed 12 
cycles of amplification (95°C for 10 s, 60°C for 10 s, and 72°C for 170 s). In the 
second round of PCR, a lambda-specific primer (Lambda T) and a HIV-1 LTR-
specific primer (AA55M) were used (Table 1), so that only LTR-containing products 
from the first-round PCR could be amplified. Nested PCR was performed on 1/10 
of the first-round PCR product in a mixture comprising 1× Light Cycler 480 Probe 
Master (Roche Diagnostics), 300 nM Lambda T primer, 300 nM AA55M primer, 
and 200nM (each) hybridization probes LTR FL and LTR LC (Table 1). The nested-
PCR cycling profile began with a denaturation step (95°C for 8 min), followed by 50 
cycles of amplification (95°C for 10 s, 60°C for 10 s, and 72°C for 9 s). 
Two-LTR circles were detected with primers spanning the LTR-LTR junction (HIV F 
and HIV R1, Table 1). Reaction mixtures contained 1× Light Cycler 480 Probe 
Master (Roche Diagnostics), 300 nM (each) forward and reverse primers, and 200 
nM (each) fluorogenic hybridization probes HIV FL and HIV LC (Table 1) in a final 
volume of 20 µl. After an initial denaturation step (95°C for 8 min), the cycling 
profile was 15 cycles consisting of 95°C for 10 s, 66°C for 10 s, and 72°C for 10 s, 
followed by 35 cycles at the beginning of which the annealing temperature was 
decreased by 0.5°C per cycle to the secondary target temperature (59°C). 
As an internal standard for normalizing the amount of cellular genomic DNA, the 
level of human β-globin DNA was quantified. The reaction was carried out using 1× 
Light Cycler 480 Probe Master (Roche Diagnostics), 400 nM of forward primer 
BGF, 400 nM of reverse primer BGR, and 200 nM of BGX-P fluorescent probe 
(Table 1). The amplification conditions included a hot start at 50 °C for 2 min and 
95 °C for 10 min, followed by 40 cycles of denaturation at 95 °C for 15 s and 
extension at 60 °C for 1 min. 
Statystical Analysis 
Paired comparisons were carried out using the two-tailed Student’s t test, 
assuming equal variance between samples to determine differences at the 5% 
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level. All data points (including outliers) were included in the analysis for 
significance. 
Table 1. DNA sequences of primers and probes used in RT-Q-PCR assays. 
Primer or 
probee 
Sequence (5′−3′) Target 
Luc Fw GAAGAGATACGCCCTGGTTCC 
Luc Rev TGTGATTTGTATTCAGCCCATATCG 
Luc Probe* TTCATAGCTTCTGCCAACCGAACGGACAa 
Total HIV-1 DNA 
L-M667 ATGCCACGTAAGCGAAACTCTGGCTAACTAGGGAACCCACTG 
Alu 1 TCCCAGCTACTGGGGAGGCTGAGG 
Alu 2 GCCTCCCAAAGTGCTGGGATTACAG 
Integrated HIV-1 
DNA (first round 
PCR) 
Lambda T ATGCCACGTAAGCGAAACT 
AA55M GCTAGAGATTTTCCACACTGACTAA 
LTR FL* CACAACAGACGGGCACACACTACTTGAb 




HIV F GTGCCCGTCTGTTGTGTGACT 
HIV R1 ACTGGTACTAGCTTGTAGCACCATCCA 
HIV FL* CCACACACAAGGCTACTTCCCTGAb 








a Modified with 6-carboxyfluorescein (FAM) at the 5′ end and with BlackBerry Quencher (BBQ) at the 3′ end. 
b Modified with fluorescein (FL) at the 3′ end. 
c Phosphorylated at the 3′ end and modified with LC red 640 dye at the 5′ end. 
d Modified with 6-carboxyfluorescein (FAM) at the 5′ end and with 6-carboxytetramethylrhodamine (TAMRA) at the 3′ 
end. 

















HIV-1 IN is acetylated by GCN5 acetyltransferase 
IN is acetylated by GCN5 in vitro: identification of the 
acetylation sites 
During the past few years, many reports have desribed the interaction of specific 
proteins encoded by a wide variety of viruses with cellular HATs. This interaction is 
often associated with the acetylation of the viral protein itself, which results in a 
modulation of its activity (Col et al., 2001; Deng et al., 2000; Kiernan et al., 1999; 
Lodewick et al., 2009; Madison et al., 2002; Mu et al., 2004; Ott et al., 1999; Poulin 
et al., 2004; Shimazu et al., 2006; Xie et al., 2002; Zhang et al., 2000). Indeed, a 
specific interaction between HIV-1 IN and p300 has been recently reported, leading 
to the acetylation of three lysine residues in the CTD of the viral protein (Cereseto 
et al., 2005; Topper et al., 2007). Since acetylation substrates are often targeted by 
multiple HATs, we sought to investigate whether IN might be acetylated by 
enzymes other than p300. It has already been reported that MOZ and PCAF 
(belonging to the MYST and GNAT families of HATs, respectively) are incapable to 
efficiently acetylate the IN CTD in vitro (Topper et al., 2007). Therefore, in the 
present study, another member of the GNAT family, GCN5, was examined. 
To determine whether IN is a substrate for GCN5 catalytic activity, in vitro 
acetylation assays were performed with recombinant IN and GCN5, both purified 
as GST fusion proteins. Incubation of the single GST domain with GCN5 in the 
presence of [14C]-labeled acetyl-CoA, and subsequent protein resolution by SDS-
PAGE followed by autoradiography led to the appearance of a unique radiolabeled 
band at the same size as GST-GCN5, corresponding to the auto-acetylation 
product of the enzyme (Figure 10A, lane 1). Incubation of GST-IN with GST-GCN5 
resulted in two major radiolabeled bands, the higher corresponding to auto-
acetylated GST-GCN5 and the lower to GST-IN (Figure 10A, lane 2), clearly 
deriving from GCN5-mediated incorporation of [14C]-acetyl groups into the viral 







Figure 10. HIV-1 IN is acetylated by GCN5 in vitro. (A) Autoradiography (upper panels) and 
Coomassie Blue staining (lower panels) of in vitro acetylation assay with recombinant GST-GCN5 and 
IN wild type or mutant proteins. Lanes 1-7: GST fusion IN proteins; lanes 8-15: 6×His-tagged IN 
proteins. In the Coomassie panels, IN proteins used as acetylation substrates are indicated by 
asterisks; in the autoradiograms, IN proteins found positive for GCN5-mediated acetylation are indicated 
in the same way. Presented results are representative data from triplicate in vitro acetylation assay 
experiments. (B) Results of densitometric analysis of autoradiograms derived from three independent 
experiments (means ± standard errors of the means [SEM]) expressed as percent wild type IN 
acetylation. (C) Schematic representation of IN proteins used for the acetylation assays. The positions 
of lysines in the CTD of IN are indicated. Lysines positive for acetylation are shown in red. 
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To define which region of IN is acetylated by GCN5, GST-IN fragments with 
progressive deletions starting from the C-terminus (as schematized in Figure 10C) 
were used as substrates in in vitro acetylation assays and the corresponding 
acetylation signals in the autoradiograms evaluated by densitometric analysis 
(Figure 10B, left histogram). GST-IN fragment 1-272 was acetylated to a similar 
extent as full-length IN (Figure 10A, compare lanes 2 and 3, and Figure 10B, left 
histogram). Acetylation of fragment 1-263 (Figure 10A, lane 4) was reduced by 
30% (Figure 10B, left histogram), while a more significant decrease in the 
radioactive signal (ranging from 60 to 70%) was detected by using shorter 
fragments (1-243, 1-234, and 1-212) (Figure 10A, lanes 5-7, and Figure 10B, left 
histogram). These results indicated that IN is acetylated by GCN5 within the region 
located between amino acid 244 and the C-terminus of the protein. As 
schematically represented in Figure 10C, this region contains five lysines at 
positions 244, 258, 264, 266, and 273 as possible targets for acetylation. 
Therefore, in order to identify the acetylated residues and exclude that the reduced 
acetylation level of the deleted IN forms derived from improper protein folding, 
each of these lysines was replaced with an arginine, an amino acid that conserves 
a positively charged side chain however cannot be acetylated. The resulting 
mutants were tested in vitro as substrates for GCN5 activity. In this experiment, IN 
was tagged at the N-terminus with a 6×His epitope in place of GST, in order to 
obtain better SDS-PAGE resolution between the signals deriving from acetylated 
GCN5 and IN (Figure 10A, lane 8). As reported in the right histogram of Figure 
10B, densitometric analysis of radioactivity incorporation highlighted that mutation 
of individual lysines 258, 264, 266 and 273 (Figure 10A, lanes 10-13) caused a 
reduction in the acetylation level of IN ranging from 40 to 50%, while no significant 
decrease in the autoradiographic signal was detected upon mutation of lysine 244 
(Figure 10A, lane 9). From these data we inferred that GCN5 acetylates IN at 
residues 258, 264, 266, and 273. Notably, previous reports demonstrated that 
another cellular HAT, p300, acetylates lysines 264, 266 and 273 in the CTD of IN 
(Cereseto et al., 2005; Topper et al., 2007). To confirm that GCN5 acetylates lysine 
258 in addition to the above-mentioned residues, two mutant forms of IN were 
produced and assayed for in vitro acetylation: one containing mutations at the sites 
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acetylated by both GCN5 and p300 (IN K264,266,273R), and the other carrying the 
additional lysine-to-arginine substitution at position 258, specifically modified by 
GCN5 (IN K258,264,266,273R). Densitometric analysis of the resulting 
autoradiogram revealed that the decrease in the radioactive signal detected with IN 
K264,266,273R was similar to the one obtained with the single-mutated IN forms 
(compare lane 14 with lanes 10-13 in Figure 10A, and right histogram of Figure 
10B), while the residual acetylation level of IN K258,264,266,273R dropped to 20 
% with respect to wild type IN (Figure 10A, lane 15, and Figure 10B, right 
histogram), likely due to the mutation introduced at lysine 258. Taken together, the 
results of in vitro acetylation assays indicated that GCN5 acetylates lysines 264, 
266 and 273 of IN, previously identified as p300 target sites, and lysine 258 as a 
specific site of modification. 
IN is acetylated by GCN5 in vivo: detection of IN acetylation by a 
novel anti-acetylated IN antibody 
Next, we investigated whether IN is also acetylated by GCN5 in vivo. To this aim, 
c.o. Flag-IN (Limon et al., 2002) was expressed in HEK 293T cells, alone or 
together with HA-GCN5 wild type or carrying two inactivating mutations in the 
catalytic HAT domain (Y260A/F261A) (Paulson et al., 2002). Immunoprecipitation 
of IN and subsequent Western blot analysis with an antibody specific to acetylated 
lysines revealed the highest acetylation signal in the sample corresponding to IN 
coexpressed with wild type GCN5 (Figure 11A, upper panel, lane 3). Conversely, 
expression of IN alone, or together with catalytically inactive GCN5, resulted in 
lower acetylation signals, likely deriving from the activity of endogenous HATs on 
the viral protein (Figure 11A, upper panel, lanes 2 and 4). In this experiment, the 
total amounts of immunoprecipitated IN and the expression levels of wild type and 
mutant GCN5 were verified by Western blot analysis with anti-Flag and anti-HA 
antibodies, respectively (Figure 11A, middle and lower panels). 
To confirm the in vitro observation that IN is a substrate for both GCN5 and p300, 
an antibody specific to acetylated IN was produced by using for immunization a 
peptide corresponding to amino acids 261-280 of the IN sequence, chemically 
acetylated at lysines 264, 266 and 273, which are targeted in common by the two 
HATs (see the Material and Methods chapter for details). As shown in Figure 11B, 
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the purified antibody specifically recognized the acetylated IN peptide used as 
immunizing epitope in dot-blot experiments, while no cross-reactivity was detected 
with the unmodified IN peptide or acetylated BSA. By using this antibody for the 
analysis of IN immunoprecipitated from cell lysates, basal levels of IN acetylation 
due to the activity of endogenous HATs could be detected, as well as higher 
acetylation levels induced by exogenously expressed p300 (Figure 11C, top-left 
panel, lanes 1 and 2, respectively). This result is consistent with our previous 
study, showing that p300 catalyzes IN acetylation in vivo at positions 264, 266 and 
273 (Cereseto et al., 2005). Conversely, no acetylation signal was detected with 
immunoprecipitated IN K264,266,273R, expressed in the cells either alone or 
together with p300 (Figure 11C, top-left panel, lanes 3 and 4), thus revealing the 
high specificity of the newly developed antibody. In this experiment, the amount of 
IN (wild type or mutated) immunoprecipitated in each sample was verified by 
Western blotting with an anti-Flag antibody (Figure 11C, bottom-left panel). The 
anti-acetylated IN antibody was also used for straight Western blot analysis of cell 
lysates. In these experimental conditions, basal levels of IN acetylation induced by 
endogenous HATs could not be revealed, likely due to lesser amounts of IN 
present in the cell lysates as compared to samples containing the 
immunoprecipitated protein (Figure 11C, top right panel, lane 5). However, the 
antibody was able to detect IN acetylation in the cell lysate corresponding to IN 
coexpressed with p300 (Figure 11C, top right panel, lane 6), thus exhibiting higher 
sensitivity than the standard anti-acetyl-lysine antibodies, which require an 
immunoprecipitation step to reveal IN acetylation, even upon coexpression of the 
acetylating enzyme. Given the high specificity and sensitivity of the anti-acetylated 
IN antibody, it was used to confirm the in vivo acetylation of IN by GCN5, as well as 
the mapping of the targeted lysines performed in vitro. As shown in the upper panel 
of Figure 11D, extracts from HEK 293T cells coexpressing wild type IN and GCN5 
revealed a remarkable signal corresponding to IN acetylation (lane 4), while, 
consistently with the data reported in Figure 11C (top-right panel, lane 5), 
acetylation of the viral enzyme by endogenous HATs was almost undetectable 
(lane1). Conversely, no signal at all was detected upon immunoblotting of cell 
lysates containing triple- or quadruple-mutant IN, expressed either alone (lanes 2 
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and 3) or together with GCN5 (lanes 5 and 6). In this experiment, Western blot 
analysis of the cell extracts was also performed with anti-Flag and anti-HA 
antibodies to control the levels of exogenously expressed proteins. From these 
results we concluded that GCN5, in addition to p300, is able to acetylate IN in vivo 
at lysines 264, 266, and 273. 
 
Figure 11. IN is acetylated by GCN5 in vivo. (A) Extracts from HEK 293T cells transfected with the 
indicated plasmids were immunoprecipitated using anti-Flag antibody and analyzed by Western blotting 
with anti-acetyl-lysine antibody (upper panel) or anti-Flag antibody (middle panel). Lower panel: cell 
extracts immunoblotted with anti-HA antibody. (B) Acetylated BSA and peptides corresponding to IN 
amino acids 260-281, either chemically acetylated at lysines 264, 266, and 273, or not acetylated, were 
blotted onto a nitrocellulose filter and incubated with anti-acetylated IN antibody. (C) Left panels (lanes 
1-4): extracts from HEK 293T cells transfected with the indicated plasmids were immunoprecipitated 
using anti-Flag antibody and analyzed by Western blotting with anti-acetylated IN antibody (top panel) 
or anti-Flag antibody (bottom panel). Right panels (lanes 5-8): extracts from HEK 293T cells transfected 
with the indicated plasmids analyzed by Western blotting with anti-acetylated-IN antibody (top panel) or 
anti-Flag antibody (bottom panel). (D) Extracts from HEK 293T cells transfected with the indicated 
plasmids analyzed by Western blotting with anti-acetylated-IN antibody (upper panel), anti-Flag antibody 
(middle panel), or anti-HA antibody (lower panel). 
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In conclusion, data obtained from the in vitro and in vivo analysis of IN acetylation 
collectively indicated that IN is specifically modified by GCN5 at four lysine 
residues located in the C-terminal domain at positions 258, 264, 266, and 273. 
IN interacts with GCN5 
IN interacts with GCN5 in vivo 
Since IN acetylated by GCN5, the interaction between the two proteins in living 
cells was investigated. To this aim, Flag-IN was expressed in HEK 293T cells 
together with HA-GCN5 wild type or mutated in the catalytic domain 
(Y260A/F261A) and immunoprecipitated using an anti-Flag antibody. As shown in 
the upper panel of Figure 12A, Western blot analysis of the immune complexes 
with an anti-HA antibody revealed that both wild type and mutant GCN5 specifically 
coprecipitated with Flag-IN (lanes 3 and 4), while they did not with the Flag epitope 
expressed from pFlag empty vector (lane 2). Accordingly, in the reciprocal 
experiment, where immunoprecipitation with an anti-HA antibody was followed by 
immunoblotting with an anti-Flag antibody, IN specifically coprecipitated with HA-
GCN5 (both wild-type and mutant forms) (Figure 12B, upper panel, lanes 3 and 4), 
while it did not with the HA epitope expressed from pcDNA3-HA empty vector 
(Figure 12B, upper panel, lane 2). In both experiments, the total amounts of 
immunoprecipitated proteins and the expression levels of IN and GCN5 were 
verified by Western blotting (Figure 12A and B, middle and lower panels). Notably, 
both wild type GCN5 and its catalytically inactive mutant were able to coprecipitate 
with IN, thus indicating that the interaction between the two proteins does not 
depend on the HAT activity of GCN5. 
IN interacts with GCN5 in vitro: mapping of the regions involved 
in the interaction 
After the in vivo detection of the IN/GCN5 interaction, we set out to dissect the 
regions that mediate the binding between the two proteins. 
To map the region of IN mediating the interaction with GCN5, GST pull-down 
assays were carried out between GST-GCN5 immobilized on glutathione-
Sepharose beads and IN deleted forms labeled with [35S]-Met by in vitro 
translation. The IN fragments tested for interaction with GCN5 contained 
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progressive deletions starting from the C-terminus of the protein, corresponding to 
those used in in vitro acetylation assays (and schematized in Figure 10C). As 
shown in Figure 12C, the affinity of IN fragments 1-272 and 1-263 to GST-GCN5 
(13% binding efficiency) was similar to that of full-length IN (16% binding 
efficiency). Conversely, the interaction with GST-GCN5 was significantly decreased 
by using IN fragments (1-243 and 1-234) that contained further deletions towards 
the N-terminus (p < 0.05 and p < 0.01, respectively). These results indicated that 
the C-terminal region of IN located between amino acids 244 and 288, which 
contains the lysines targeted for acetylation, is involved in binding to GCN5. 
To map the IN interacting regions on GCN5, the latter was divided into four 
fragments, which were subsequently expressed and purified as GST fusion 
proteins. Therefore, four GST-GCN5 deleted forms were produced (as 
schematized in Figure 12D), corresponding to regions encompassing amino acids 
1-189 (N-terminal domain), 190-270 (HAT domain), 271-383 (intermediate 
domain), and 384-476 (bromodomain). These fragments, together with the full-
length protein, were tested in GST pull-down assays for interaction with in vitro 
translated IN, labeled with [35S]-Met. As shown in Figure 12E, IN bound to GCN5 
fragments 1-189 and 271-283 with significantly lower efficiency (p < 0,05) than to 
the full-length protein, while no significant differences were detected in the affinity 
of IN to GCN5 HAT domain or bromodomain as compared to full-length GCN5, 
thus suggesting that these regions of the protein are mainly responsible for the 
interaction with IN. This result is consistent with the HAT domain being the catalytic 
portion of the enzyme, that has to contact the substrate in order to transfer the 
acetyl group, and the bromodomain being an amino acidic module with specific 
binding affinity to acetyl-lysine residues (Dhalluin et al., 1999; Hudson et al., 2000; 
Owen et al., 2000). 
Taken together, data obtained in GST pull-down experiments indicated that the 
HAT domain and bromodomain are involved in mediating GCN5 binding to the 




Figure 12. IN interacts with GCN5 both in vitro and in vivo. (A) Extracts from HEK 293T cells 
transfected with the indicated plasmids were immunoprecipitated using anti-Flag antibody and analyzed 
by Western blotting with anti-HA antibody (upper panel) or anti-Flag antibody (middle panel). Lower 
panel: extracts immunoblotted with anti-HA antibody. (B) Extracts from HEK 293T cells transfected with 
the indicated plasmids were immunoprecipitated using anti-HA antibody and analyzed by Western 
blotting with anti-Flag antibody (upper panel) or anti-HA antibody (middle panel). Lower panel: extracts 
immunoblotted with anti-Flag antibody. (C) Autoradiography and Coomassie Blue staining of in vitro 
binding assays with GST-GCN5 and 35S-IN or the indicated 35S-IN fragments. The histogram represents 
the results of three independent experiments (means ± SEM), where the amounts of bound proteins are 
expressed as percentages of the corresponding radiolabeled inputs. Statistical significance of the 
binding percentages was calculated by using the Student’s two-sided t test. Asterisks directly above 
bars indicate differences in binding efficiency to GST-GCN5 between IN deleted forms and full-length 
IN. **, P < 0,01; *, P < 0,05. Conversely, where asterisks are not present, values obtained did not 
significantly differ (P > 0,05) from those obtained with full-length IN. (D) Schematic representation of the 
functional domains of human GCN5 (hGCN5 wt) used for the binding assay reported in (E). N-ter: N-
terminal domain; HAT: HAT domain; Inter: Intermediate domain; BrD: Bromodomain. (E) 
Autoradiography (upper panel) and Coomassie Blue staining (lower panel) of in vitro binding assay with 
35S-IN and GST-GCN5 or the indicated GST-GCN5 fragments. The histogram represents the results of 
three independent experiments (means ± SEM), where the amounts of bound IN are expressed as 
percentages of the input of radiolabeled protein. Statistical significance of the binding percentages was 
calculated by using the Student’s two-sided t test. Asterisks directly above bars indicate differences in 
binding efficiency to IN between GST-GCN5 deleted forms and GST-GCN5 full-length. *, P < 0,05. 
Conversely, where asterisks are not present, values obtained did not significantly differ (P > 0,05) from 
those obtained with GST-GCN5 full-length. 
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Acetylation by GCN5 enhances IN catalytic activity in 
vitro 
Production of constitutively acetylated recombinant IN by 
tethered catalysis 
To explore the effect of GCN5-mediated acetylation on the catalytic activity of IN, 
constitutively acetylated recombinant IN was produced by exploiting the “tethered 
catalysis” approach (Acharya et al., 2005; Guo et al., 2004). This method allows 
the production of a constitutively acetylated protein by tethering the factor of 
interest to the catalytic domain of a specific HAT enzyme. Based on this approach, 
as schematized in Figure 13A, a chimeric construct was generated where c.o. IN, 
tagged at the N-terminus with a 6×His epitope, was fused at its C-terminal end with 
the region of GCN5 encompassing amino acids 6-300, which includes the catalytic 
HAT domain. To obtain a control that cannot be acetylated, the same chimera was 
constructed by using the inactive mutant of GCN5 Y260A/F261A. In addition, a 
sequence encoding TEV protease recognition site was inserted between IN and 
GCN5 coding sequences to allow the separation of the two domains. Wild type and 
mutant GCN5 fusions were expressed in bacteria, purified from total cell lysates by 
metal ion affinity chromatography, and finally digested with TEV protease. The 
reaction mixtures were resolved by SDS-PAGE and Coomassie Blue staining of 
the resulting gel revealed, in the lanes corresponding to proteolytically processed 
samples, a band migrating at the same size as 6×His-tagged IN, clearly deriving 
from the removal of GCN5 moiety from the fusion protein (Figure 13B, compare 
lanes 3 and 5 with lanes 2 and 4). Most importantly, recombinant IN derived from 
the wild type GCN5 fusion resulted in a remarkable positive signal upon 
immunoblotting with an anti-acetyl-lysine antibody, while the mutant allele of GCN5 
failed to generate a significant level of IN acetylation (Figure 13C, top panel, 
compare lanes 1 and 3 with lanes 2 and 4). In this experiment, the amounts of 
loaded proteins were verified by incubating the same blotted membrane with an 
antibody directed against IN (Figure 13C, bottom panel). 
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In vitro integration assays with constitutively acetylated 
recombinant IN 
Constitutively acetylated recombinant IN and the non-acetylated control were 
tested in vitro for 3′-end processing and strand transfer activities. In the 3′-end 
processing reaction, recombinant IN was incubated with a 21-mer, [32P]-labeled 
double stranded oligonucleotide mimicking one end of the viral DNA (S), in the 
presence of a divalent metal ion. The reaction mixture was analyzed by gel 
electrophoresis followed by autoradiography, and the excision of 2 nucleotides 
from the 3′-end of the labeled strand was evaluated by measuring the radioactive 
signal deriving from the 19-mer product (P). Acetylated IN (100 or 200 ng, lanes 1 
and 3 of Figure 13D, respectively) proved to be two- to three-fold more active than 
the non-acetylated control (100 or 200 ng, lanes 2 and 4 of Figure 13D, 
respectively), as revealed by comparative densitometric analysis of the 
radiolabeled bands corresponding to the 3′-end processed template (Figure 13D, 
compare lanes 1 and 3 with lanes 2 and 4). IN strand transfer activity was 
evaluated by using the same [32P]-labeled DNA substrate as in the 3′-end 
processing assay. Following separation of the reaction products from the substrate 
by gel electrophoresis and subsequent autoradiography, signals derived from the 
ladder of higher molecular weight species (P) generated in the reaction, migrating 
slower than the original 21-mer substrate, were used to quantify IN strand transfer 
activity. Consistent with the 3′-end processing results, densitometric analysis of the 
resulting autoradiogram highlighted that constitutively acetylated IN, used at two 
different doses (100 or 200 ng), was five- to ten-fold more active in catalyzing the 
strand transfer reaction than the corresponding non-acetylated controls (Figure 
13E, compare lanes 1 and 3 with lanes 2 and 4). Taken together, these results 
indicated that GCN5-mediated acetylation enhances the catalytic activity of IN in 




Figure 13. GCN5-mediated acetylation increases the catalytic activity of IN in vitro. (A) Schematic 
representation of IN-GCN5 tethered catalysis constructs. Full-length IN, tagged with a N-terminal 6×His 
epitope, is fused in frame with TEV proteolytic site and cloned upstream of the 6-300 amino acid region 
of wild type GCN5 (IN-GCN5 wt) or its catalytically inactive allele (IN-GCN5 mut). (B) Coomassie Blue 
staining of IN-GCN5 fusion proteins before and after TEV protease-mediated digestion. Lane 1: 6×His-
tagged IN; lane 2: IN-GCN5 wt before proteolytic processing; lane 3: products derived from digestion of 
IN-GCN5 wt with TEV protease; lane 4: IN-GCN5 mut before proteolytic processing; lane 5: products 
derived from digestion of IN-GCN5 mut with TEV protease. (C) 1 µg and 2 µg of IN derived from IN-
GCN5 wt (lanes 1 and 3, respectively), or 1 µg and 2 µg of IN derived from IN-GCN5 mut (lanes 2 and 
4, respectively) were analyzed by Western blotting with anti-acetyl-lysine antibody (top panel) or anti-IN 
antibody (bottom panel). (D) 3′-end processing activity of IN derived from IN-GCN5 wt (lane 1: 100 ng; 
lane 3: 200 ng) or IN-GCN5 mut (lane 2: 100 ng; lane 4: 200 ng). Lane 5: DNA substrate; lane 6: DNA 
substrate with 40 ng of 6×His-tagged IN. (E) Strand transfer activity of IN derived from IN-GCN5 wt (lane 
1: 100 ng; lane 3: 200 ng) or IN-GCN5 mut (lane 2: 100 ng; lane 4: 200 ng). Lane 5: DNA substrate; 
lane 6: DNA substrate with 40 ng of 6×His-tagged IN. In (C) and (D), the DNA substrate (S) and the 
catalytic products (P) are indicated. 
HIV-1 infectivity is reduced in GCN5 knockdown cells 
In order to evaluate the role of the interaction between IN and GCN5 and the 
consequent acetylation of IN during the HIV-1 replication cycle, viral infectivity upon 
GCN5 depletion in target cells was analyzed. Transient knockdown of GCN5 
expression was obtained in HeLa cells by transfection with a chemically 
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synthesized siRNA targeting nucleotides 1364 to 1382 of GCN5 mRNA (siGCN5), 
while a non-targeting siRNA, unrelated to any human genomic sequence, was 
used as a negative control (Ctrl siRNA). For stable silencing of GCN5 expression, 
specific HEK 293T cell lines were generated by the use of lentiviral vector-encoded 
shRNAmirs. shRNAmirs represent a new generation of shRNAs, modeled after 
endogenous microRNAs (miRNAs) (Zeng et al., 2002). For our experiments, pGIPZ 
lentiviral vectors, purchased from Open Biosystems (Huntsville, AL), were 
employed. Since the addition of sequences from human microRNA-30 (miR30) has 
been reported to greatly increase the silencing potential of expressed hairpins 
(Silva et al., 2005), shRNAs are expressed from pGIPZ vectors as human miR30 
primary transcripts. The shRNAmir insert thus comprises a hairpin stem made of 
22 nt of double stranded DNA, specifically targeting the mRNA of interest, a 19 nt 
loop derived from human miR30, and 125 nt of the miR30 flanking sequence 
located on either side of the silencing hairpin (Figure 14A). In addition, the 
shRNAmir insert is cloned in frame with a puromycin drug resistance marker for the 
selection of stably transduced cells, and expressed as part of a bicistronic 
transcript together with TurboGFP, thus allowing the visual marking of shRNAmir-
positive cells (Figure 14B). 
 
 
Figure 14. pGIPZ shRNAmir-
containing lentiviral vectors. (A) 
Schematic illustration showing that 
silencing shRNAs are expressed from 
pGIPZ lentiviral vectors as human 
miR30 primary transcripts. (B) 
Schematic representation of pGIPZ 




HEK 293T cells were transduced with a pGIPZ vector encoding a shRNAmir 
specifically annealing to the 3′ untranslated region (3′ UTR) of GCN5 mRNA 
(GCN5 shRNAmir) and, after puromycin-mediated selection, the three cell clones 
with the highest TurboGFP expression levels, as determined by FACS analysis, 
were chosen. As non-silencing controls, two HEK 293T polyclonal cell lines were 
developed, one expressing a mismatched, non-targeting GCN5 shRNAmir (GCN5 
shRNAmir mut), and the other carrying an empty pGIPZ vector, which lacks a 
silencing insert. As shown in Figure 15A, Western blot analysis of the cell lysates 
with an antibody directed against GCN5 revealed that the expression level of the 
protein was significantly reduced in both transiently and stably silenced cells with 
respect to controls (top panels), while tubulin expression was similar in all the 
samples (bottom panels). The efficiency of knockdown was similar in siRNA-
treated and shRNAmir-expressing cells. Silenced cells were infected with an env-
deleted, VSV-G pseudotyped NL4.3 virus expressing the luciferase reporter gene 
(indicated hereafter as NL4.3-Luc) and luciferase activity in the cell lysates was 
measured 48 hours after infection. As shown in Figure 15B, a two- to three-fold 
reduction in luciferase activity was detected in both transiently and stably silenced 
cells, thus indicating that knockdown of GCN5 expression in target cells reduces 
HIV-1 infectivity. To determine which step of viral replication was affected by GCN5 
depletion, cells were harvested at various time points after infection and 
measurements of the different HIV-1 DNA species were performed by RT-Q-PCR. 
Total HIV-1 DNA was quantified with the use of primers annealing to the luciferase 
reporter gene, in order to avoid cross-reaction with the integrated pGIPZ lentiviral 
vectors present in stably transduced HEK 293T cell lines. In fact, primers most 
commonly used for the detection of total HIV-1 DNA anneal in the U5 region of the 
LTR and the 5′-end of the gag gene. Since analogous sequences are present in 
the pGIPZ lentiviral vectors used for the generation of stable GCN5 knockdown cell 
clones and the corresponding non-silenced controls, the use of these primers 
would result in a very high background “noise”, from which the signal deriving from 
infection with NL4.3-Luc could not be distinguished. As shown in Figure 15C, no 
significant alterations in total HIV-1 DNA levels were detected in cells either 
transiently or stably silenced, thus indicating that reverse transcription was not 
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affected by the reduction of GCN5 expression. To detect integrated HIV-1 DNA, 
siRNA-treated HeLa cells were analyzed 48 hours post infection by Alu-LTR nested 
PCR (see the Material and Methods chapter for details), while stably transduced 
HEK 293T cell lines were processed two weeks after infection using primers 
specific to the luciferase reporter gene. This was necessary in order to dilute non-
integrated HIV-1 DNA and avoid cross-reaction with the integrated pGIPZ lentiviral 
vectors. Proviral DNA was about two-fold less in all GCN5 knockdown cells, either 
treated with siRNA or transduced with shRNAmir-encoding lentiviral vectors (Figure 
15D). Finally, a two-fold increase in the amount of 2-LTR circles was detected in 
both stably and transiently silenced cells (Figure 15E). Since the increase in 2-LTR 
circles often correlates with a defect at the step of integration (Engelman, 1999), 
these data are collectively consistent with reduced integration efficiency in GCN5 
knockdown cells. Therefore, we concluded that the presence of GCN5 in target 






Figure 15. GCN5 depletion in 
infected cells reduces HIV-1 
integration. (A) Left panels: extracts 
from siRNA-treated Hela cells 
analyzed by Western blotting with 
anti-GCN5 antibody (top) or anti-α-
tubulin antibody (bottom). Lane 1: 
cells transfected with non-targeting 
siRNA (Ctrl siRNA); lane 2: cells 
transfected with GCN5-targeting 
siRNA (siGCN5). Right panels: 
extracts from stable GCN5 
knockdown HEK 293T cell clones or 
control cell lines immunoblotted with 
anti-GCN5 antibody (top panel) or 
anti-α-tubulin antibody (bottom 
panel). Lane 3: untransduced HEK 
293T cells; lane 4: HEK 293T cells 
carrying empty pGIPZ vector; lane 5: 
HEK 293T cells expressing mutant, 
non-targeting GCN5 shRNAmir; 
lanes 6-8: HEK 293T clones (Cl8, 
Cl9 and Cl13) expressing GCN5 
shRNAmir. (B) siRNA-treated Hela 
cells (left histogram) or HEK 293T 
cells stably transduced with pGIPZ 
lentiviral vectors (right histogram) 
were infected with NL4.3-Luc and 
analyzed for luciferase activity 48 
hours after infection. The histograms 
represent percentages of luciferase 
activity relative to control, non-
silenced cells. Means ± SEM from 
three independent experiments are 
reported. (C-E) Total DNA extracted 
from siRNA-treated Hela cells (left 
histograms) or HEK 293T cells 
stably transduced with pGIPZ 
lentiviral vectors (right histograms) 
was analyzed by RT-Q-PCR for total 
HIV-1 DNA (C), integrated HIV-1 
DNA (D) and 2-LTR circles (E). In 
(C-E), results are presented as 
percentages relative to control, non-
silenced cells. Reported values are 
means ± SEM from three 
independent experiments. Statistical 
significance values shown in (B-E) 
were calculated by using the 
Student’s two-sided t test. Asterisks 
directly above bars indicate differences between knockdown and control, non-silenced cells. ***, P < 
0,001; **, P < 0,01; *, P < 0,05. Conversely, where asterisks are not present, values obtained did not 
significantly differ (P > 0,05) from those obtained with control, non-silenced cells. 
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Mutations at IN acetylation sites reduce HIV-1 
integration efficiency and replication capacity 
Reduced integration efficiency of HIV-1 viruses mutated at IN 
acetylation sites in single round infections 
Since GCN5 depletion in target cells results in decreased HIV-1 infectivity, which 
specifically correlates with less efficient provirus formation, we decided to explore 
the effects of arginine substitutions introduced in the virus at the GCN5-targeted 
lysine positions of IN. To this aim, a NL4.3-Luc HIV-1 clone expressing quadruple-
mutant IN (IN K258,264,266,273R) was generated (NL4.3-Luc 4mut). In addition, 
since IN lysines acetylated by GCN5 partially overlap with those targeted by p300, 
we set out to compare the replication properties of the IN quadruple-mutant virus 
with those of a corresponding HIV-1 clone carrying lysine-to-arginine substitutions 
at IN positions 264, 266, and 273, which are acetylated in common by the two 
HATs (NL4.3-Luc 3mut). Therefore, env-deleted, VSV-G pseudotyped NL4.3-Luc 
viral clones, bearing three or four mutations at the IN acetylation sites, were used 
to infect HEK 293T cells in single-round replication assays, together with the 
corresponding virus expressing wild type IN. Forty-eight hours after infection, 
measurements of luciferase activity in the cell lysates revealed that both mutant 
viruses were five-fold less infective than wild type (Figure 16A). To determine 
which step in the viral replication cycle was affected by the mutations introduced in 
the IN sequence, total DNA was extracted from cells harvested at various time 
points after infection, and the different HIV-1 DNA species were measured by RT-
Q-PCR. By the use of primers annealing to the luciferase reporter gene present in 
NL4.3-Luc viral clones (wild type or mutated), similar levels of total HIV-1 DNA 
were detected at 24 hours post infection in cells infected with NL4.3-Luc 3mut or 
4mut, as well as with wild type virus (Figure 16B). This finding indicated that the 
activity of HIV-1 RT was not perturbed by the mutations introduced in the IN 
sequence, so that the resulting viruses proved able to successfully accomplish 
reverse transcription. Integrated HIV-1 DNA was quantified at 48 hours post 
infection by Alu-LTR nested PCR (see the Materials and Methods chapter for 
detail). As a result, a five-fold reduction in the number of proviruses was detected 
upon infection with both mutant viruses with respect to wild type (Figure 16C). 
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These data indicated reduced HIV-1 integration efficiency upon mutation of IN 
lysines targeted by acetylation. Consistently, cells infected with NL4.3-Luc 3mut or 
4mut exhibited a three-fold increase in the amount of 2-LTR circles as compared to 
cells infected with wild type virus (Figure 16D), thus confirming a specific defect in 
the viral replication cycle at the step of integration and no alterations during PICs 
nuclear import. Notably, the IN triple- and quadruple-mutant viruses exhibited 
almost identical reductions in infectivity and integration efficiency with respect to 
wild type. Therefore, IN lysines 264, 266 and 273, which are acetylated in common 
by GCN5 and p300, appear to be required for HIV-1 to integrate with maximal 
efficiency and be fully infectious, while IN lysine 258, although specifically modified 
by GCN5 in vitro, does not seem to play any significant role in the viral replication 
cycle. 
HIV-1 clones mutated at IN acetylation sites exhibit delayed 
peaks of replication and reduced virus production in multiple 
round infections 
Next, the role of IN acetylated lysines during HIV-1 replication in a T cell line was 
investigated. To this aim, two NL4.3-derived viral clones were generated, 
expressing either the triple- or quadruple-mutant IN (NL4.3 3mut and NL4.3 4mut, 
respectively). One million CEM T cells were infected with the resulting viruses 
using two different amounts of p24 antigen (10 or 1 ng). HIV-1 replication was 
monitored by measuring RT activity in the culture supernatants every three days 
over a period of 21 days. As shown in Figure 16E, cells infected with the higher 
viral load (10 ng p24 antigen) of wild type virus exhibited a peak of HIV-1 
replication around day 9 post infection. Conversely, cells infected with same 
amounts of NL4.3 3mut or 4mut reached the RT production peak at day 12 post 
infection, thus with three days of delay as compared to cells infected with wild type 
virus. Notably, in these experimental conditions, the RT amounts produced by both 
mutant HIV-1 clones at the infectivity peaks were approximately half of the one 
obtained upon infection with the wild type virus. By using the lower viral load (1 ng 
p24 antigen), the replication curve of wild type NL4.3 started to raise quite steeply 
around day 12 post infection, while, for both mutant viruses, the replication curves 
started to appear at day 15. Detectable RT production was observed for both 
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NL4.3 3mut and 4mut at day 18, thus with 6 days of delay as compared to wild 
type virus (Figure 16F). In conclusion, as determined by tracking viral growth 
through culture, viruses carrying mutations at the IN acetylation sites exhibited 
delayed peaks of replication with respect to wild type in both the experimental 
conditions used (10 or 1 ng p24 antigen per 1×106 CEM T cells), as well as half 
reduced RT production at the infectivity peak upon infection with the higher viral 
load. Similarly to the results obtained in single-round infections, mutations 
introduced in the virus at IN sites targeted in common by GCN5 and p300 (K264, 
K266 and K273), or additional mutation at lysine 258, specifically acetylated by 
GCN5 in vitro, reduced the replication capacity of the virus to the same extent. 
 
Figure 16. Mutations at IN acetylation sites in the virus cause a replication defect at the step of 
integration. (A) HEK 293T cells infected with NL4.3-Luc/IN WT, NL4.3-Luc/IN K264,266,273R, or 
NL4.3-Luc/IN K258,264,266,273R were analyzed for luciferase activity 48 hours after infection. (B-D) 
Total DNA extracted from HEK 293T cells infected with the same viral clones as in (A) was analyzed by 
RT-Q-PCR for total HIV-1 DNA at 24 hours after infection (B), integrated HIV-1 DNA at 48 hours after 
infection (C) and 2-LTR circles at 24 hours after infection (D). In (A-D), results are presented as 
percentages relative to cells infected with NL4.3-Luc/IN WT. Reported values are means ± SEM from 
three independent experiments. Statistical significance values shown in (A-D) were calculated by using 
the Student’s two-sided t test. Asterisks directly above bars indicate differences between cells infected 
with mutant viruses and cells infected with wild type virus. ***, P < 0,001; **, P < 0,01. Conversely, 
where asterisks are not present, values obtained did not significantly differ (P > 0,05) from those 
obtained with cells infected with wild type virus. (E) RT activity detected in the culture supernatants of 
CEM cells at different time points after infection with NL4.3/IN WT, NL4.3/IN K264,266,273R, or 


















Acetylation of the IN CTD by cellular HATs 
After the finding that IN is a substrate for p300-mediated acetylation and the 
identification of three lysines in the IN CTD that are targeted by this PTM (Cereseto 
et al., 2005; Topper et al., 2007), the results of the present study reveal that GCN5 
is an as-yet-unidentified cellular HAT catalyzing the acetylation of IN both in vitro 
and in vivo. Notably, the IN region acetylated by GCN5 partially overlaps with the 
one targeted by p300 in the CTD of the protein. Indeed, IN lysines 264, 266 and 
273 appear to be common substrates for the two HATs. However, in vitro 
mutagenesis experiments performed here highlighted that recombinant GCN5 is 
able to acetylate an additional lysine residue in the CTD of IN, located at position 
258. In fact, lysine-to-arginine substitutions at IN positions 264, 266 and 273 
almost abolished p300-mediated acetylation in vitro (Cereseto et al., 2005; Topper 
et al., 2007). Conversely, in vitro acetylation assays performed with recombinant 
GCN5 revealed that IN K264,266,273R was acetylated to a similar extent as the 
single-mutated IN forms, while the additional lysine-to-arginine substitution 
introduced at position 258 significantly reduced the acetylation level of the protein 
(see Figure 10A-B in the Results chapter). From these data we concluded that four 
lysines in the CTD of IN, located at positions 258, 264, 266 and 273, are acetylated 
by recombinant GCN5 in vitro. Therefore, specific targeting of lysine 258 by GCN5 
appears to distinguish the in vitro catalytic activities of the two HATs on IN. 
The results of in vitro acetylation assays, showing that IN is an efficient substrate 
for both GCN5- and p300-catalyzed acetylation, were validated in vivo by 
exogenously expressing IN and the putative acetylating enzyme, either GCN5 or 
p300, in HEK 293T cells. Notably, the experiments performed in this study go 
beyond the analysis of the IN acetylation level in cell extracts with an anti-
acetylated lysine antibody. In fact, by the use of an antibody developed ad hoc for 
the recognition of IN acetylated at lysines 264, 266 and 273, we were able to 
extend our in vitro observations about the specificity of the IN acetylation reactions 
catalyzed by GCN5 and p300 to in vivo circumstances, demonstrating that the 
three residues at positions 264, 266 and 273 are specifically targeted by both 
HATs also, and most importantly, in a physiological context (see Figure 11C-D in 
the Results chapter). This finding is of particular relevance, since it represents the 
Discussion 
 106 
first demonstration that the IN CTD is acetylated in the cells at lysines 264, 266 and 
273 by two different HATs, GCN5 and p300. A similar situation, where different 
cellular HATs modify the same sites on the target protein, has been reported for 
another HIV-1 factor, Tat, which is acetylated at lysines 50 and 51 by p300/CBP 
and GCN5, leading in both cases to an enhancement of Tat-dependent 
transcriptional activation of the viral LTR promoter (Col et al., 2001; Deng et al., 
2000; Kiernan et al., 1999; Ott et al., 1999). The finding that, although divergent in 
sequence, belonging to different HAT families and involved in distinct signaling 
pathways, GCN5 and p300 converge to acetylate IN on the same sites may be 
attributed to the importance of the acetylation of lysines 264, 266 and 273 in the 
function of IN, since it would provide a “fail-safe” mechanism capable of 
maintaining adequate levels of IN acetylation at these key sites under varying 
cellular conditions. Accordingly, the fact that the three lysines, which are common 
substrates for acetylation by GCN5 and p300, are highly conserved among 
different HIV-1 strains (Lu et al., 2005) also suggests that their preservation is 
important for some aspect of viral replication. 
IN acetylated lysines are located within the HAT- 
interacting region 
Co-immunoprecipitation experiments performed in the present study revealed that 
IN and GCN5 specifically interact in the cells (see Figure 12A-B in the Results 
chapter). In vitro binding assays with GST-GCN5 and IN fragments containing 
progressive deletions starting from the C-terminus allowed the mapping of the 
region involved in the interaction with the HAT enzyme between residue 244 and 
the C-terminus of the viral protein (see Figure 12C in the Results chapter). 
Therefore, the portion of IN involved in the interaction with GCN5 also contains the 
acetylated residues (located at positions 258, 264, 266 and 273). This is true also 
in the case of p300, since it directly binds to IN within a region located in the CTD 
of the protein between amino acids 264 and 288 (Cereseto et al., 2005) and 
acetylates three residues, at positions 264, 266 and 273, that are included in this 
same region (Cereseto et al., 2005; Topper et al., 2007). Therefore, previous and 
present studies highlighted that, for both GCN5 and p300, the portion of IN 
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involved in the binding to the HAT enzyme also comprises the residues modified by 
acetylation. 
Interestingly, our mapping of the IN regions interacting with the HAT enzymes, as a 
result of in vitro binding assays, is consistent with a recent report presenting two 
three-dimensional models of full-length IN complexed with GCN5 and p300 (Di 
Fenza et al., 2009). Both models predict that the IN C-terminal tail located between 
amino acids 271 and 288, due to its high flexibility, could easily adapt to the 
binding pocket of GCN5, as well as to that of p300 (Figure 17). Interestingly, IN 
lysine 273 is included in this unstructured region, and is therefore expected to be 
the residue most prone to acetylation. In fact, since IN lysines 264 and 266 are 
located in close proximity to a sandwich of two three-stranded antiparallel β sheets, 
their binding and acetylation would require a more complex unfolding of this stable 
secondary structure. Based on this model, we may hypothesize IN lysine 273 to be 
the first residue contacted and acetylated by the HAT enzyme, either GCN5 or 
p300. This event might in turn induce a conformational change in the C-terminal 
portion of IN, which could facilitate the modification of the other two lysines (as will 
be discussed later in this paragraph). This hypothesis is also compatible with the 
data reported by Topper and coworkers, demonstrating a hierarchy of reactivity 
between the three residues modified by p300, with lysine 273 as the primary target 
for acetylation (Topper et al., 2007). 
The finding that the IN region interacting with GCN5 also contains the acetylated 
lysines is particularly interesting, especially when taking into consideration the 
results of our in vitro binding experiments aimed at the determination of the IN-
interacting domains of GCN5. In fact, the HAT domain and bromodomain of GCN5 
proved to be mainly responsible for the interaction with the C-terminal portion of IN 
(see Figure 12E in the Results chapter). Given the fact that the bromodomain 
functions as a protein module that specifically binds to acetyl-lysine-containing 
motifs (Yang, 2004a), the involvement of GCN5 bromodomain in the interaction 
with the IN region in which the acetylation sites are located raises the possibility 
that the IN acetylated residues could provide a recognition motif for the 
bromodomain of GCN5. A possible scenario is thus that, following acetylation of 
one or more residues on IN, the interaction between GCN5 bromodomain and the 
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acetylated lysines of IN provides additional links that strengthen the interaction 
between the two proteins. Several examples of such a mechanism have been 
reported in literature. For instance, the myogenic transcription factor MyoD is 
acetylated by p300/CBP and PCAF at lysines 99 and 102. MyoD acetylated 
residues are then recognized by the bromodomain of CBP, resulting in a 
strengthened interaction between the HAT and MyoD itself. This event finally 
results in a more efficient recruitment of HAT complexes to muscle-specific 
promoters, on which they acetylate other substrates, such as histones (Polesskaya 
et al., 2001). Given the hierarchy of reactivity that was established between IN 
lysines 264, 266 and 273, based both on experimental data (Topper et al., 2007) 
and three-dimensional models (Di Fenza et al., 2009), with residue at position 273 
being the primary target for acetylation, the modification of IN at this site may 
trigger the recognition of the acetylated residue by the bromodomain of GCN5 and 
affect the interaction between the two proteins in such a way that promotes the 
modification of the other target lysines in the IN CTD. This kind of mechanism may 
also fit in with p300, since our previous experiments (data not shown) revealed that 
the p300 bromodomain is also involved in the interaction with the C-terminal 
portion of IN containing the acetylated lysines at positions 264, 266 and 273. 
 
Figure 17. Three-dimensional models of IN complexes with GCN5 and p300. (A) Three-dimensional 
model of the IN/GCN5 complex. IN is represented in green and GCN5 in light grey. (B) Three-
dimensional model of the IN/p300 complex. IN is represented in green and p300 in light grey. In (A) and 
(B), the three lysine residues in the CTD of IN that are acetylated by both GCN5 and p300 (Lys 264, Lys 
266 and Lys 273) are shown in yellow. GCN5 and p300 are rendered as surfaces, while IN as a cartoon 
to highlight the C-terminal unfolded portion, which inserts in the binding pockets of the two HATs. 
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Comparative analysis of GCN5 and p300 function in 
HIV-1 integration 
Since IN lysines 264, 266 and 273 are common substrates for GCN5 and p300 in 
in vitro acetylation assays, while lysine 258 appears to be a GCN5-specific site of 
modification, we performed a comparative analysis aimed at establishing the roles 
of the two HATs during the HIV-1 replication cycle. Viral clones mutated at the IN 
sites targeted in common by GCN5 and p300 (K264, K266 and K273), or carrying 
the additional lysine-to-arginine substitution at position 258 were generated. The 
resulting mutant viruses were used, together with their wild type counterpart, either 
to infect HEK 293T cells in single-round viral replication assays, or for multiple-
round infections of CEM T cells. In all the experimental conditions tested, both 
mutant viruses proved to be less infective than the wild type. Quantification of the 
different HIV-1 DNA species in HEK 293T infected cells by RT-Q-PCR revealed 
that the infectivity decrease specifically correlated with less efficient provirus 
formation by the mutant viral clones as compared to wild type (see Figure 16A-D in 
the Results chapter). Notably, infections with IN triple- or quadruple-mutant viruses 
resulted in similar reductions in the levels of HIV-1 integrated DNA with respect to 
wild type, leading to identical decreases in infectivity. These results indicated that 
acetylation of IN C-terminal lysines 264, 266 and 273, which are substrates for both 
GCN5 and p300, is required for the virus to integrate with maximal efficiency and 
be fully infectious, while acetylation of IN lysine 258, although specifically catalyzed 
by GCN5 in vitro, does not seem to play any significant role during the HIV-1 
replication cycle, since the additional amino acidic substitution introduced at this 
site in the context of the triple-mutant virus does not furtherly affect its replication 
capacity. However, it cannot be excluded that the apparent discrepancy between 
our in vitro and in vivo results (i.e. in vitro detection of GCN5-mediated acetylation 
of IN at lysine 258, with no functional outcome in vivo) may be due to an intrinsic 
limitation of in vitro acetylation assays performed with recombinant HAT enzymes. 
In fact, in such experiments, the activity of HATs is investigated as they would exist 
in the cell as individual proteins, while it is well established that HAT enzymes are 
subunits of large multiprotein complexes, and do not seem to exist individually in 
the cell. Moreover, it has been demonstrated that the different subunits of distinct 
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HAT-containing complexes can change the substrate specificity of the respective 
HAT enzymes. Therefore, it seems conceivable that the affinity towards the IN C-
terminal lysines of the cellular GCN5-containing complexes may be slightly 
different from that of the isolated recombinant protein in vitro. 
Notably, even if the comparative analysis of viral clones mutated at the IN sites 
acetylated by GCN5 or p300 points to redundant functions of the two HATs in 
regulating the activity of IN, the analysis of viral replication upon GCN5 depletion in 
target cells suggests that GCN5 and p300 play partially overlapping, yet distinct 
roles during the step of integration. In fact, the reduced infectivity, paralleled by 
lower provirus formation, which was detected upon infection of GCN5 knockdown 
cells (see Figure 15B and D in the Results chapter), indicates that endogenous 
p300 is not able to compensate for the loss of GCN5 so as to allow the virus to 
integrate with maximal efficiency and fully restore the sensitivity of GCN5-depleted 
cells to HIV-1 infection. The view of GCN5 and p300 having partially overlapping, 
yet not completely redundant roles in regulating IN function is also supported by 
the results of our in vitro integration assays, showing that GCN5-mediated 
acetylation enhances the catalytic activity of IN both in 3′-end processing and 
strand transfer reactions, while the acetylation of IN catalyzed by p300 stimulates 
the strand transfer, but doesn’t affect the 3′-end processing activity of the viral 
enzyme (Cereseto et al., 2005). 
The reduced integration efficiency of HIV-1 clones 
mutated at IN acetylated lysines is due to a lack of 
acetylation 
The decreased HIV-1 infectivity detected in GCN5 knockdown cells, which is 
paralleled by a similar reduction in the level of integrated HIV-1 DNA (see Figure 
15B and D in the Results chapter), indicates that the integration defect observed 
upon mutation of the IN acetylated lysines in the virus results from a loss of 
acetylation, rather than from functional changes in the protein induced by the 
amino acidic substitutions. In fact, the replication properties of wild type NL4.3-Luc 
virus in cells where GCN5 expression has been transiently or stably silenced 
closely resemble those of NL4.3-Luc 3mut and 4mut viral clones in non-silenced 
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cells, in the sense that, in both the experimental conditions, the replication cycle of 
HIV-1 exhibits a specific defect at the step of integration, while reverse transcription 
and PICs nuclear import remain unaffected, as revealed by RT-Q-PCR detection of 
the different HIV-1 DNA species at various time points after infection. In this 
respect, it is conceivable that the integration defect observed upon mutation of the 
IN acetylation sites in the virus is more severe than the one observed upon GCN5 
depletion in target cells (five- against two-fold reduction in provirus formation), 
since lysine-to-arginine substitution precludes the acetylation of the target sites by 
any cellular HAT, while in GCN5 knockdown cells other HATs may, at least in part, 
substitute for the lack of GCN5 activity. The first candidate suited to compensate 
for the loss of GCN5 is, of course, p300, since we have shown that IN lysines 264, 
266 and 273 are common substrates for the two HATs; however, a participation of 
PCAF in substituting for the lack of GCN5 cannot be excluded. In fact, GCN5 and 
PCAF are highly homologous HATs and an upregulation of PCAF expression in 
response to the loss of GCN5 has been documented in different cell lines (Kikuchi 
et al., 2005) (Nagy et al., 2010), suggesting that when GCN5 is inactivated, cells try 
to compensate the loss of its activity with that of its paralogue. 
A recent debate: the role of IN acetylation during the 
replication cycle of HIV-1 
The results of our in vitro integration assays demonstrate that GCN5-mediated 
acetylation of IN increases the catalytic activity of the protein, both in 3′-end 
processing and strand transfer reactions (see Figure 13D-E in the Results chapter). 
p300-catalyzed acetylation also enhances IN strand transfer activity, as reported in 
our previous work (Cereseto et al., 2005). This is not surprising, since IN lysines at 
positions 264, 266 and 273 are common substrates for the two HATs. Therefore, 
our previous and present studies suggest that one of the mechanisms through 
which acetylation of IN C-terminal lysines promotes HIV-1 integration is by 
enhancing the catalytic activity of the viral enzyme. 
While it is clear that the acetylation of IN stimulates its catalytic activity in vitro, the 
role of this PTM during the HIV-1 replication cycle has been the subject of a recent 
debate. Our previous study showed that the replication level of a HIV-1BRU clone 
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expressing a Flag-tagged triple-mutant IN (Flag-IN K264,266,273R) was severely 
impaired, and the replication deficiency was specifically due to a block at the 
integration step (Cereseto et al., 2005). A subsequent report by Topper and 
coworkers (Topper et al., 2007) presented contrasting results. The authors found 
that the virus expressing untagged triple-mutant IN was fully replication competent, 
exhibiting only a slight integration defect. In fact, as determined by a genetic 
integration assay based on the stable transduction of a dominant selectable 
marker, the integration frequency of the IN triple-mutant virus was about 60% of 
that of wild type, which did not preclude sustained viral replication in culture. 
Additional data on the topic came from a report by Apolonia and coworkers 
(Apolonia et al., 2007). Here, the integration efficiency of a HIV-derived lentiviral 
vector carrying lysine-to-arginine substitutions at IN positions 264, 266 and 273 
was evaluated, in the context of a study aimed at the development of integration-
deficient lentiviral vectors to be used as gene therapy tools. The IN K264,266,273R 
mutant vector exhibited a five-fold lower transgene expression than its wild type 
counterpart at fourteen days after transduction, indicating reduced viral DNA 
integration into the host cell genome. Quantification of the IN triple-mutant vector 
background integration by the same genetic assay used by Topper and coworkers 
revealed a fourteen-fold lower residual integration rate than the wild type vector. In 
the present study, we sought to clarify the role of IN acetylation during the HIV-1 
replication cycle. To this aim, we performed single- and multiple-round infections 
with HIV-1 clones encoding IN either mutated at the lysine positions targeted in 
common by GCN5 and p300 (IN K264,266,273R), or carrying the additional lysine-
to-arginine substitution at the site specifically modified by GCN5 in vitro (IN 
K258,264,266,273R). In multiple-round replication assays, the mutant HIV-1 clones 
exhibited delayed infectivity peaks and reduced virus production with respect to 
wild type (see Figure 16E-F in the Results chapter). The discrepancy of these 
findings with the data reported by Topper and coworkers (Topper et al., 2007) may 
be partially due to the different time-courses of analyses: although working in the 
same experimental conditions (10 ng of p24 antigen per 1×106 CEM T cells), 
detection of RT activity in the culture supernatants over a period of twenty-one 
days allowed us to monitor the peak of viral replication, while Topper and 
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coworkers terminated the replication curve before the highest point of infectivity 
was reached (at twelve days post infection). However, in our previous report 
(Cereseto et al., 2005), the introduction of lysine-to-arginine substitutions at IN 
positions 264, 266 and 273 in the virus resulted in a more severe replication defect 
than the one observed here. The different extent to which HIV-1 replication was 
affected by the mutations at IN acetylation sites in our previous and present studies 
may be likely due to the fact that the earlier finding was obtained by using viral 
clones containing a Flag-tag epitope fused downstream and in frame with the C-
terminus of IN, as suggested in the report by Topper et al (Topper et al., 2007). 
In single-round viral replication assays, consistent with the transgene expression 
data reported by Apolonia and coworkers (Apolonia et al., 2007), both the IN triple- 
and quadruple-mutant viruses exhibited a five-fold decrease in infectivity, which 
was paralleled by a five-fold reduction in the number of proviruses, as detected by 
RT-Q-PCR (see Figure 16 A and C in the Results chapter). 
In our opinion, the results obtained in this study, together with those presented in 
previous reports, support the notion of the IN CTD acetylation by cellular HATs 
representing a mechanism through which the efficiency of HIV-1 integration is 
modulated, contributing to create the appropriate conditions for the virus to reach 
full infectivity, rather than serving as a simple “on/off” switch. The relevance of IN 
acetylation to HIV-1 infectivity has been recently highlighted by the finding that the 
cellular protein KAP1 specifically interacts with acetylated IN leading to HDAC1 
recruitment and IN deacetylation (Allouch et al., 2011). Kap1 complex formation 
with IN ultimately determines integration impairment, thus suggesting a role for this 
host factor in an innate restriction mechanism in human cells that targets HIV-1 
replication by specifically affecting the efficiency of the integration process. The 
development of a cellular defense mechanism targeting acetylated IN further 
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